	Dummy variable of Hospital C	Educational background	Research experience	Knowledge on EBN

Setting 	B=1.331 t=2.807 P= 0.005			B=-1.151 t=2.807 P=0.005

Nurse 		B=-0.995 t=-2.048 P= 0.041

Presentation 	B=0.951 t=2.318 P= 0.021		B=-2.398 t=-4.716 P= 0.000

Barriers scale	B=3.396 t=2.415 P= 0.016		B=-4.234 t=-2.429 P= 0.015

Facilitators scale	B=0.925 t=2.417 P=0.016


Pseudomonas aeruginosa strains	Bacteriocidal (+)	Bacteriostatic (−)

PAO1	+

PA103	+

PA14	 	−

Clinical strain	 	−


Accession	Transcription factor family	Log2 fold

Up-regulated genes

AK322452	DREB3	2.5

BP893968	AP2d	2.7

AK320001	RAV2	2.7

AK319979	Pti4	3.4

AW034241	ERF2	4.3

AW651406	bZIP	2.6

AK224603	bZIP	2.8

AK326827	bZIP	3.1

EU636698	CONSTANS-like Zinc Finger	3.5

AJ784616	Stress-associated protein 6 (Zinc finger)	6.7

BG627283	BTF3-like (NAC)	2.9

AK324393	NAM-like	5

BM412776	WRKY	5.8

AK322575	WRKY3	14.5

TC239950	TCP	2.5

AK319300	TCP transcription factor 14	3

TA41176_4081	GRAS 6	3.3

AK325371	Putative transcription factor	3.4

BP879218	Putative Squamosa promoter-binding protein	3.5

Down-regulated genes

DB690655	CONSTANS-LIKE 16 Zinc Finger	3.9

DB697244	CONSTANS-LIKE 9 Zinc Finger	5.5

AW624869	CONSTANS-LIKE 10 Zinc Finger	6.8

AW622759	WRKY	3.9

AK247980	WRKY	5.2

AK247135	PIF1 (bHLH)	2.5

BI935893	putative bHLH	2.4

AK327992	MADS box	4

AK327530	PHD finger	2.2

BI925618	Bell-like homeodomain protein 2 (POX domain)	2.2

BI921917	Tubby-like F-box protein	2.6


REACH category and action	Identified priority programmes

Livestock and fisheries

Animal husbandry, fisheries, and insect farming	• Backyard poultry production in Nepal

• Household animal and horticulture production in Ghana

• Aquaculture development in Uganda

• Aquaculture development and nutrition education in Uganda

• School livestock programme in Ethiopia

• Conditional livestock transfer in Ethiopia

• Targeted cash and chicken transfer in Uganda

Crops/horticulture

Diversification and locally adapted varieties	• Home gardens in India

• Kitchen gardens in Bangladesh

• School‐based fruit production in Tanzania

• Home gardens and small livestock production in Uganda

• Home gardens and small livestock production in Bangladesh

Food processing, fortification, and storage

Food processing (excl. fortification)	• Complementary food processing programme in Ghana

Fortification (including salt iodization and fortification of complementary foods)	• Point of consumption fortification in Nepal

• Micronutrient sachets for home fortification in India

• Home‐based fortified flour production in Nepal

• Complementary food production in Ethiopia

• Mass media campaign on fortification with dried fish in Nigeria

Food consumption practices for healthy diets

Food‐based nutrition education	• School‐based feeding and nutrition education in Ethiopia

• Adolescent health and nutrition education in South Asia

• School‐based nutrition education in Ghana

• School‐based nutrition education in Uganda

• School‐based agriculture education in Ghana

Creating supportive environments to promote healthy diets in different settings	• School snack programme in Nepal

• Preschool feeding in Bangladesh

Enabling environment

Fiscal policy	• Milk transport subsidy in Nepal (livestock and fisheries)

• Decreasing transport costs in Tanzania (food consumption)

• Rice subsidy in Nigeria (food processing, fortification, and storage)

• Food tax and subsidy in Ghana (food consumption)

• Solar drier subsidy in Nepal (food processing, fortification, and storage)

Legislation, regulations/standards, protocols, and guidelines	• Food marketing association in Ghana (food consumption)

• Improved traditional wet markets in Tanzania (food consumption)

• Local market development in Nepal (food consumption)

• Quality assurance for infant complementary food (food consumption)

• Government quality certification seal (food consumption)

• Integrating nutrition into agriculture and health services in Tanzania (crops/horticulture)

Social norms: Education/sensitization, behaviour change communication, and social marketing	• Technology‐enabled behaviour change communication in Nigeria (food consumption)

• Nutrition education and media campaign in India (food consumption)

• Diet diversity media campaign in India (food consumption)

• Maternal nutrition media campaign in India (food consumption)

• Media and education campaign in Ethiopia (food consumption)

• Edutainment in Ethiopia (food consumption)

Vouchers or transfers (not defined by REACH)

	• Targeted and conditional cash transfer in India

	• Conditional cash transfer in Nigeria

	• Conditional cash and food transfers in Bangladesh

	• Food vouchers in India

	• Food vouchers in Tanzania

	• Conditional food transfer in Ethiopia


	Family history of AA	Coronary heart disease	Hypertension	Cerebrovascular disease	Diabetes

AA (n = 169)	2	68	103	22	17

Non-AA (n = 156)	0	27	38	2	10

p value		0.000*	0.000*	0.000*	0.234


Gene	Main associated phenotype	Gene product	Inheritance	Age of onset	Diagnostic clues

ADCY5	ADCY5-related chorea	Adenylate cyclase 5	AD/de novo	Infancy to childhood	Axial hypotonia and delayed milestonesDiurnal and sleep-related MD exacerbationsDystonia and myoclonus prominent in some cases

PDE10A	PDE10A-related chorea	Phosphodiesterase 10A	De novo/AD/AR	Infancy to childhood	Delayed motor-language milestones and dysarthria in recessive casesMRI: symmetrical T2-hyperintense bilateral striatal lesions in cases with heterozygous de novo mutations

FOXG1	Congenital Rett disease	Forkhead Box G1	De novo	Infancy to early childhood	Severe ID, absent language, acquired microcephalyMRI: corpus callosum aplasia/hypoplasia, delayed myelination, simplified gyration

ARX	Early infantile epileptic encephalopathy-type 1;X-linked mental retardation	Aristaless-related homeobox protein	XL	Infancy	Ohtahara/West syndrome, severe mental retardation, generalized dystonia/dyskinesias with recurrent status dystonicus

STXBP1	Early infantile epileptic encephalopathy-type 4	Syntaxin-binding protein 1	De novo	Early infancy to childhood	Onset of seizures within one year of age. Developmental delay, ID, autistic-like features, ataxia with or without dyskinesias/dystonia

SYT1	Severe motor delay and intellectual disability	Synaptotagmin-1	De novo	Infancy	Severely delayed motor development without seizures

UNC13A	Congenital encephalopathy with dyskinesias	Unc-13 homolog A	De novo	Congenital	Developmental and speech delay; ID, congenital dyskinesias with intention tremor, rare febrile seizures

GNAO1	Early infantile epileptic encephalopathy type 17/Ohtahara syndrome	Gαo subunit of GPCR	De novo	Infancy to childhood	Developmental delay and IDLong-lasting MD exacerbations not related to sleepEpilepsy can be absent or well controlled

GRIN1	Mental retardation, autosomal dominant 8	GluN1 subunit of NMDAR	De novo/AR	Infancy	Severe developmental delay and IDEarly-onset epileptic seizuresOculogyric crisesCortical blindness, dysmorphic traits, microcephaly

FRRS1L	Early infantile epileptic encephalopathy-type 37	Ferric Chelate Reductase 1-like	AR	Infancy	Psychomotor regression after normal developmentSevere encephalopathic epilepsyChoreo-athetosis in infancy/childhood, parkinsonism in adolescence

TBC1D24	Early infantile epileptic encephalopathy type 16	TBC1 domain family, member 24	AR	Infancy	Early-onset myoclonic seizuresVariable degrees of IDDystonia

GPR88	GPR88-related chorea	G protein-coupled receptor 88	AR	Infancy to childhood	Developmental and language delaySevere mental retardationScarcely progressive chorea

KMT2B	DYT28 dystonia	lysine-specific histone methyltransferase 2B	De novo/AD	Childhood-adolescence	Onset in lower limbs and prominent oro-mandibular/laryngeal involvementMild dysmorphic traits; mild IDGood and sustained response to pallidal DBS

ATP1A3	AHCRDPCAPOS syndrome	Na+/K+ ATPase, α3 subunit	De novo/AD	Infancy to fifth decade	Abrupt onset of neurological signs (dystonia, muscular weakness, ataxia)Initial hemisomatic distributionIdentifiable triggering factors


	Number of events	Event rate per 100 person years (95% CI)

Any Stroke	22	4.0 (2.3–5.6)

Posterior circulation stroke	12	2.1 (0.9–3.3)

Any stroke or TIA	41	7.9 (5.5–10.4)

Posterior circulation stroke or TIA	26	4.8 (3.0–6.7)


 	Parasite density based on assumed WBC count	Parasite density based on measured WBC count	P value*

P. falciparum (n = 143)	15,208 (9,320-19,470)	13,213 (7,680-16,273)	0.49

P. vivax (n = 33)	5,364 (644-10,109)	3,538 (595-12,698)	0.96


Premature Ejaculation Profile Questions	Tramadol	Paroxetine	Placebo

Satisfaction with sexual intercourse (Z)	−5.31	−3.55	−1.10

p-value	0.0001	0.0001	0.270

Control over ejaculation (Z)	−5.39	−2.22	−0.09

p-value	0.0001	0.026	0.923

Ejaculation-related interpersonal difficulty (Z)	−4.001	−2.34	−1.90

p-value	0.0001	0.019	0.057

Ejaculation-related distress (Z)	−3.97	−2.29	−0.81

p-value	0.0001	0.022	0.417


Variables	Patients with RVSD (N = 32)	Patients without RVSD (N = 13)	p-value

Right atrial end-systolic area, cm2	19.7 ± 7.6	15.8 ± 8.1	0.149

Right atrial length, mm	42.9 ± 10.2	42.5 ± 11.1	0.916

Right ventricular basal diameter, mm	49.6 ± 9.3	47.7 ± 10.7	0.583

TAPSE, mm	13.1 ± 2.6	20.3 ± 2.2	<0.001*

Right ventricular S’, cm/s	10.6 ± 3.2	15.3 ± 3.9	<0.001*

RIMP	1.09 ± 0.60	1.76 ± 1.30	0.032*

RV wall thickness, mm	3.6 ± 1.2	3.5 ± 0.8	0.952

Tricuspid Valve E:A ratio	1.21 ± 0.44	0.90 ± 0.35	0.019*

Tricuspid Valve E/e’	5.08 ± 2.73	3.46 ± 1.45	0.023*

Left atrial diameter, mm	43.2 ± 6.4	41.9 ± 6.2	0.548

LV end-diastolic diameter, mm	62.0 ± 7.5	62.4 ± 11.7	0.910

LV ejection fraction, %	32.4 ± 9.3	36.6 ± 7.7	0.127

LV stroke volume index, L/m2	39.9 ± 12.3	51.4 ± 17.9	0.017

Anti-log10 mitral valve E:A	1.50 ± 0.62	1.31 ± 0.25	0.154

Mitral valve E/e’	15.96 ± 7.13	15.61 ± 7.06	0.882

PA acceleration time, ms	61.8 ± 22.4	78.9 ± 28.0	0.037*

PA systolic pressure, mmHg	47.4 ± 19.4	39.2 ± 21.5	0.246

Mean PAP, mmHg	30.6 ± 11.6	25.9 ± 13.1	0.273

Pulmonary hypertension	23 (71.9 %)	7 (53.9 %)	0.304


Segments	Primers	Position	Length, bp

Internal standard

 P1	5′-aacatacccatggccaacct-3′	3304–3836	533

 P2	5′-ggcaggagtaatcagaggtg-3′

First cycle

 P3	5′-tgaacctacgagtacaccga-3′	7901–14220	1342

 P4	5′-ttagtagtagttactggttg-3′

Second cycle

 P5	5′-ttcatgcccatcgtcctaga-3′	8201–13851	673

 P6	5′-gttgaggtctagggctgtta-3′

Third cycle

 P7	5′-cccctctagagcccactgtaaagc-3′	8282–13650	391

 P8	5′-ggggaagcgaggttgacctg-3′


Variables	aAdjusted HR	95% CI	P value

Age (years)	1.033	1.027–1.039	< 0.001

Female sex	0.700	0.593–0.827	< 0.001

Hypertension	1.025	0.897–1.172	0.713

Diabetes mellitus	1.427	1.216–1.675	< 0.001

Preoperative severe anemia(Hb < 8.0 g/dL)	1.282	1.036–1.586	0.022

Preoperative creatinine (mg/dL)	2.022	1.711–2.389	< 0.001

Postoperative creatinine (mg/dL)	1.010	1.004–1.017	0.003

Intraoperative use of normal saline	1.030	0.905–1.172	0.656

Postoperative hyponatremia	1.331	1.148–1.542	< 0.001


Variables	Explanation

Measures of needs

Age-adjusted mortality

Physician density	The number of physicians who work for any medical facilities per 1,000 population

Hospital physician density	The number of physicians who work for hospitals per 1,000 population

Clinic physician density	The number of physicians who work for clinics per 1,000 population

Measures of residential quality

Urban/rural status	The metropolitan area code defined by the Ministry of Internal Affairs and Communications

1) urban centres, 2) suburban areas,

3) rural areas

Per capita income

Percent of the population	As a proxy for educational level in the community

with a university-level education

Unemployment rate	The number of unemployed individuals per the number of all individuals currently in the labour force (workforce)

Percent of white-collar workers	The number of professionals, technical workers, managers, and administrators per number of workforce

Primary school students per number	As a proxy for children’s educational opportunities

of primary schools

Crime rate	The number of crimes per total population as a proxy for neighbourhood safety

Temperature	As a proxy for climate discomfort. The discomfort index was calculated by using temperature and humidity and used in the model.

Humidity

Other factors

Total population

Hospital beds per 1,000 population

The presence or absence of	As a proxy for continuing education

medical schools


	Cut off point	Sensitivity	Specificity	PPV	NPV

Morphology(%)	5.5	66%	94%	96%	31%

Motility(%)	72.5	29%	94%	94%	26%

Concentration(million/ml)	35.5	46%	94%	96%	32%


	Penciclovir cream (P)	Acyclovir cream (A)	Ratio (P/A)	Statistics

μg/cm2	Mean	s.e.m	Mean	s.e.m		P value

Strip 1	0.55	0.16	0.88	0.3	0.6	0.42

Strip 2	0.29	0.06	0.06	0.03	4.9	0.002

Pooled Strips	0.32	0.12	0.07	0.04	4.5	0.07

Epidermis	1.15	0.35	1.01	0.04	1.1	0.32

Dermis (residual stripped skin)	0.10	0.04	0.07	0.04	1.4	0.63

Permeation through the skin (receptor phase)	0.41	0.19	0.12	0.10	3.4	0.18

	Penciclovir cream (P)	Acyclovir cream (A)	Ratio(P/A)	Statistics

% applied dose	Mean	s.e.m	Mean	s.e.m		P value

Strip 1	1.15	0.41	0.30	0.11	3.8	0.06

Strip 2	0.61	0.16	0.02	0.01	29.1	0.002

Pooled Strips	0.67	0.31	0.02	0.01	32.3	0.04

Epidermis	2.4	0.9	0.3	0.1	7.0	0.3

Dermis (residual stripped skin)	0.17	0.07	0.02	0.01	9.1	0.06

Permeation through the skin (receptor phase)	0.68	0.33	0.04	0.03	16.7	0.06


		<underline>Percentage (%)</underline> (n = 100)	<underline>95% CI</underline>

Most frequent diagnostic categories *

	Neoplasm and chemotherapy	15	9 – 24

	Respiratory infections	9	4 – 16

	Asthma	5	2 – 11

	Gastroenteritis	5	2 – 11

	Appendicitis	4	1 – 10

	Epilepsy or seizure	3	0.6 – 9

	Malfunctioning device or graft	3	0.6 – 9

Length of stay

	1 day	10	5 – 18

	2 days	25	17 – 35

	3 days	24	16 – 34

	4–7 days	27	17 – 37

	8 to 103 days	14	8 – 22

Devices *

	Gastrostomy or jejuenostomy tubes	10	5 – 18

	Central venous line	7	3 – 14

	Medication nebulizer	7	3 – 14

	Ventriculoperitoneal shunt	2	0.2 – 7

	Tracheotomy	1	0.03 – 5

Number of medications §

	0	18	11 – 27

	1	20	13 – 29

	2	26	18 – 36

	3	16	10 – 26

	4	7	3 – 14

	5 or more	12	6 – 20

Number of daily medication administrations noted ‡

	0 or PRN	33	24 – 44

	1–4	30	21 – 40

	5–9	24	16 – 34

	10–22	12	6 – 20

Home nursing care	8	4 – 15

Other forms of home care	7	3 – 14

Disposition

	Home	91	84 – 96

	Transfer	3	0.6 – 9

	Death	1	0.03 – 6

	Unknown	5	2 – 11


Income group	Mean reduction in daily calorie intake (kcal/person/day)

Female	Male	Overall

Income group 1 (lowest)	2.2	1.6	1.9

Income group 2	1.9	1.9	1.9

Income group 3 (highest)	1.9	2.6	2.3


Trial	Number	Setting	Trial duration	ICU	Population	Intervention	Comparator	Outcomes

Inclusion criteria	Exclusion criteria

Youness et al. [20]	33	Single-centre US	24 months	Mixed	Intubated mechanically ventilated patients with new-onset (<48 h) atelectasis	CF, uncontrolled asthma, COPD, pneumothorax, pleura effusion, tumor-associated atelectasis, severe hypoxemia, hemodynamic instability, allergy to dornase alfa, use of nebulized acetylcysteine and pregnancy	Nebulized dornase alfa 2.5 mg twice daily in 7 days or until resolution of atelectasis	(1) Placebo (isotonic saline) same volume, dosage, and duration of treatment	Mortality

(2) Hypertonic saline (same volume, dosage, and duration of treatment)

Zitter et al. [19]	30	Single-centre US	12 months	Mixed	Mechanically ventilated patients aged >18 years with new-onset (<24 h) atelectasis	Quadriplegia, chronic ventilator dependence, pneumothorax, frank hemoptysis, elevated intracranial pressure, pregnancy or active nursing, concurrent use of other investigational drugs, and allergy to dornase alfa, Chinese hamster ovary-derived biologics or other components of the active component	Nebulized dornase alfa 2.5 mg twice daily until extubation, death or transfer (maximum 30 days)	Placebo (isotonic saline) same volume, dosage, and duration of treatment	Mortality


Cell Type	Number of Genes	% of Genes

adipocyte	188	21.23

alveolar macrophage	127	14.11

B-lymphoblast	106	12.58

B-lymphocyte	628	70.79

brown adipose	1	0.11

cardiac muscle cell	33	3.72

chondrocyte	33	3.72

dendritic cell	56	6.35

endothelium	194	21.88

eosinophil	1	0.11

epithelium	604	68.49

fibroblast	485	54.92

foam cell	25	2.74

germ cell	435	49.02

glial cell	432	48.69

glioblast	42	4.7

granulosa cell	63	7.22

hepatocyte	3	0.33

keratinocyte	287	32.17

leukocyte	295	33.26

lymphocyte	86	9.63

macrophage	194	21.88

mast cell	2	0.22

melanocyte	283	31.84

monocyte	13	1.42

muscle cell	233	26.37

myeloid cell	149	17.4

natural killer cell	339	38.84

neuroblast	396	44.86

neuroepithelium	143	16.19

neuron	124	14

pericyte	128	14.66

platelet	1	0.11

proerythroblast	65	7.77

promyeloblast	14	1.86

promyelocyte	44	5.03

retinal pigment epithelium	514	57.55

skeletal muscle cell	499	56.56

smooth muscle cell	128	14.77

squamous cell	376	42.67

stem cell	626	70.79

T-lymphocyte	359	40.92

transitional	194	22.21

white adipose	41	4.81


Demographic data	Control group N = 30	Endometriosis group N = 30	Ectopic group N = 22	P value (control v endometriosis)

Age, median (range)	40 (25–47)	36 (18–45)	40 (24–51)	P = 0.056

BMI, median (range)	27 (20–42)	26 (20–38)	27.1 (18–32)	P = 0.37

Parity, median (range)	2 (1–4)	1 (0–3)	1 (0–2)	P < 0.0001

Smoker	9/30 (30%)	5/30 (17%)	1/22 (5%)	P = 0.36

Endometriosis stage, median (range)	–	2 (1–4)	4 (1–4)	N/A


Challenge	CE	Matched compound	MF	RMF	Prob

1	10 eV	Kanamycin A	645	879	98.88

20 eV	Kanamycin A	501	833	98.81

30 eV	Kanamycin A	531	776	98.66


Motif	Count	Average length (bp)	Count/Mbp

Mononucleotide	19	15.89	9.35

Dinucleotide	30	29.60	14.76

Trinucleotide	92	19.99	45.26

Tetranucleotide	39	15.87	19.19

Pentanucleotide	27	16.96	13.28

Hexanucleotide	9	20.22	4.43

Total	216	19.85	106.27


Characteristic

	 n = 1,729

Age (y)	Median (IQR)	69 (62-74)

	Range	22-93

Male sex, n (%)	1,156 (66.9)

Absence of previous iodinated contrast media injections, n (%)	973 (56.3)

History of adverse reaction to iodinated contrast media, n (%)	45 (2.6)

History of allergy, n (%)	164 (9.5)

History of asthma, n (%)	23 (1.3)

Use of corticosteroid at entry, n (%)	28 (1.6)

Child–Pugh classification, n (%)

 A	1427 (82.5)

 B or C	302 (17.5)

Renal function at entry

eGFR (ml/min), Median (IQR)	 73.6 (61.7-87.3)

Presence of renal impairment, n (%)	383 (22.2)


Compounds	Content (Mean ± SD, n = 3)

mg/g

Paeoniflorin	59.55 ± 0.39

Glycyrrhizin	12.13 ± 0.01


Guarantee the follow-up and referral to medical services of individuals with a positive diagnosis

PROCESS MEASURE	Indicator description	Method of Data collection	Data Collection Frequency

Monitoring of the number of individuals infected with HIV that have received medical care	Number of individuals infected with HIV that have received medical care/Number of individuals infected with HIV attended and that have received health care by the NGO in the evaluation year	NGO	12 months

Monitoring of the number of individuals infected with HIV that are referred to other health services	Number of individuals infected with HIV that are referred to other health services/Number of individuals infected with HIV attended and that have received health care by the NGO in the evaluation year	NGO	12 months

Monitoring of the number of individuals referred to each service	Numbers of individuals referred to each service	NGO	12 months

Monitoring of the number of people working in a service	Number of people working in a service	NGO	12 months

Monitoring of the hours dedicated to each activity	Hours dedicated to each activity	NGO	12 months

OUTCOME MEASURE	Indicator description	Method of Data collection	Data Collection Frequency

Level of satisfaction with the service	Number of individuals infected with HIV that have received care, have responded to the satisfaction questionnaire, and have a high level of satisfaction/Number of infected individuals that have received care and have responded to the questionnaire	NGOAnswers to the satisfaction questionnaire	12 months

Monitoring of the questionnaire of quality of life answers of individuals attended by the NGO	Descriptive analysis and monitoring of the global score and score by dimensions of the questionnaire of quality of life answers of individuals infected with HIV and attended by the NGO	NGOAnswers to the QQV	12 months


	Heparin	Citrate

Renal days	357	199

Median renal days per patient episode	3	3

Number of filters used	408	128

Total filter cost (•)	32807.28	10292.48

Renal days per filter	0.86	1.55

Filter cost per renal day (•)	91.89	51.72

Blood transfusions per day	0.33	0.25


Run	Controllable parameter

Table separation distance	Squeegee speed	Squeegee pressure	Table speed of solder printer

1	1	1	1	1

2	1	2	2	2

3	1	3	3	3

4	2	1	2	3

5	2	2	3	1

6	2	3	1	2

7	3	1	3	2

8	3	2	1	3

9	3	3	2	1


	Men	Women	All

Study Population	46 388	46%	55 417	54%	101 805	100%

Random sample	2 300	46%	2 730	54%	5 030	100%

Study respondents	1 132	36%	2 021	64%	3 153	100%

Students who responded to the question concerning use of the web-based health advice service	1 113	36%	2 001	64%	3 114	100%

Users of the web-based health advice service	92	25%	278	75%	370	100%


Cells	Assays	BCR-ABL-GFP*	BCR-ABL-GFP + N17 H-Ras*	GFP vector*

NIH 3T3	# of foci	117 +/- 16†	11 +/- 2	-

Bone marrow	# of colonies	16 +/- 0.6	0.33 +/- 0.33	-


	β	p-value

Total effect	0.31	<0.001

Direct effect	0.25	<0.001

Total indirect	0.06	<0.001

Indirect effects

 via cravings, urges to buy, unplanned purchases	0.01	0.001

 via cravings, unplanned purchases	0.04	<0.001

 via urges to buy, unplanned purchases	0.01	0.03


Bacterial strains	G. tenax extracts dose (mg)	MIC (mg/mL)

0.3	0.6	1.2	2.5	5.0

Staphyloccocus aureus	24.3	25.1	26.4	27.7	28.9	3.9

Enterococcus faecalis	11.2	15.6	20.3	24.5	29.3	7.8

Pseudomonas aeruginosa	10.2	15.5	23.1	24.2	26.6	15.6

Escherichia coli	15.4	18.9	20.3	21.6	23.2	3.9


Form of regression model	AICc	∆AICc	wi

Time + Vegetation density + Time: vegetation density	404.97	0.00	0.99

Time + Ruggedness + Time: ruggedness	415.40	10.43	0.01

Time + Kill probability + Time: kill probability	425.81	20.84	0.00

Time + Encounter risk + Time: encounter risk	429.08	24.11	0.00

Time	436.25	31.28	0.00

Vegetation density + Ruggedness + Vegetation: ruggedness	901.25	496.28	0.00

Vegetation	904.90	499.93	0.00

Vegetation density + Encounter risk + Vegetation: encounter risk	907.93	502.97	0.00

Vegetation density + Kill probability + Vegetation: kill probability	908.53	503.56	0.00

Ruggedness	914.86	509.89	0.00

Ruggedness + Kill probability + Ruggedness: kill probability	917.95	510.93	0.00

Ruggedness + Encounter risk + Ruggedness: encounter risk	915.90	512.98	0.00

Kill probability	932.48	527.51	0.00

Encounter risk	933.88	528.91	0.00


Age (years of growth)	Number of specimen	TRR	TRM

1	5	0	1

2	8	1	2

3	8	2	3

4	8	3	4

5	5	4	5

8	3	a	8

10	1	a	10


Predictor	Estimate	Standard error	Degrees of freedom	t-value	p-value

Intercept	0.107	0.028	12.5	3.862	.002

Task	0.020	0.026	12.2	0.784	.448

Gold-MSI Musical Training	-0.003	0.001	11.1	-0.327	.750

Task * Gold-MSI Musical Training	-0.001	0.001	8.8	-0.816	.436


Device	Frequency (GHz)	Gain (dB)	Output Power (W)	PAE (%)

HPA 1	4.5–18	19	2 (CW and pulsed)	25–30%

HPA 2	5–12	20	4 (pulsed)	25–30%


Assembly

Total number of reads	1,104,651

Number of reads after pre-processing	990,945

Average read length after pre-processing	362 bp

Total number of contigs	54,748

Average contig length	965 bp

Sequencing length	52,832,938 bp

Contigs with ORF ≥200 bp (average length)	30,552 (540 bp)

Average read coverage per contig	4.34x

Average GC % content of contigs	37.77%

Annotation

% contigs with at least 1 GO term	30.01%

% contigs with an EC number	6.10%

% contigs with at least 1 IPR	33.27%

Contigs with at least 1 blast hit against nr

Total number	20,333

Average length	1,394 bp

% of those contigs with at least 1 IPR	42.61%

% of those contigs with at least 1 GO term	78.43%

Contigs with ORF ≥200 bp (average length)	18,080 (704 bp)

Contigs with no blast hits

Total number	34,416

Average length	712 bp

% of those contigs with at least 1 GO term	1.41%

% of those contigs with at least 1 IPR	28.01%

Contigs with ORF ≥200 bp (average length)	12,472 (301 bp)


Database	Without Transfer Learning	With Transfer Learning

SVM Kernel (No. PC)	APCER	BPCER	ACER	SVM Kernel (No. PC)	APCER	BPCER	ACER

ISPR-DB	RBF Kernel (No. PC = 200)	2.8438	2.8550	2.8494	Linear Kernel (No. PC = 70)	0.0313	0.0310	0.0311

Idiap (Full-DB)	RBF Kernel (No. PC = 70)	0.0000	0.0000	0.0000	Linear Kernel (No. PC = 60)	0.0000	0.0000	0.0000

Idiap (Cropped-DB)	RBF Kernel (No. PC = 105)	1.0000	1.0000	1.0000	RBF Kernel (No. PC = 95)	0.0000	0.0000	0.0000


Description of vision	Visual acuity

Good reading vision	20/20 – 20/25

Legal driving vision	20/30 – 20/40

Moderate visual loss	20/50 – 20/100

Legal blindness	≤ 20/200


Patient	Age (y)	Menopause status	Histologic type	Histological grading	B classification	MIB-1 (%)	Receptor status	Molecular subtype

				ER	PR	HER2

1	75	Post	IDC	2	5b	10	+	+	−	Luminal A

2	65	Post	IDC	2	5b	10	+	+	−	Luminal A

3	54	n.s.	IDC	3	5b	n.s.	n.s.	n.s.	n.s.	n.s.

4	39	Pre	IDC	2	5b	40	+	+	+	Luminal B

5	66	Post	IDC	2	5b	60	+	+	−	Luminal A

6	50	Pre	IDC	3	5b	50	+	+	+	Luminal B

7	73	Post	IDC	3	5b	20	+	+	−	Luminal A

8	76	Post	IDC	2	5b	20	+	+	−	Luminal A

9	63	Post	IDC	3	5	30	+	+	−	Luminal A

10	48	Post	IDC	3	5b	20	+	+	+	Luminal B

11	58	Post	IDC	n.s.	5c	20	+	+	+	Luminal B

12	61	Post	IDC	3	5b	70	−	−	−	Triple negative

13	52	Pre	ILC	n.s.	5b	50	+	+	−	Luminal A

14	42	Pre	IDC	3	5b	80	+	−	−	Luminal A

15	67	Post	IDC	3	5b	40	+	+	−	Luminal A

16	61	Post	ILC	2	5b	30	+	+	−	Luminal A

17	41	Pre	Mucinous	2	5b	50	+	+	+	Luminal B


 	Frequency	Percent

Had been asked about desire to be pregnant	95	76.8 (95%CI 68–83)

Not at risk for pregnancy	59	47.2

At risk for pregnancy (either planned or unplanned)	36	28.8

Using effective contraception	13	10.4

Using ineffective contraception**	11	8.8

Have knowledge*	10	8.0

Do not have knowledge	1	0.8

Non-contraceptive use	12	9.6

Have knowledge*	8	6.4

Do not have knowledge	4	3.2

Had never been asked about desire to get pregnant	30	24.0

Not at risk for pregnancy	23	18.4

At risk for pregnancy	7	1.56

Using effective contraception	3	2.4

Using ineffective contraception	0	0

No contraception	4	3.2

Have knowledge	2	1.6

Do not have knowledge	2	1.6


	Methodological quality featuresassessed in the included studies	Score

 A	 Description of study objectives	 1

 B	 Study design (retrospective = 0 point;prospective = 1 point; randomized prospective = 2 points)	 2

 C	 Description of sample inclusion/exclusioncriteria	 1

 D	 Intervention clearly described (reason forchoosing the extracted tooth/performing the wear)	 1

 E	 Measures for evaluating the resultsdescribed	 1

 F	 Determining the sample size (sample sizecalculation)	 1

 G	 Description of statistical analysismethods	 1

 H	 Sample description (demographic - age, sex andethnicity)	 1

 I	 Sample description (overjet, overbite,perimeter discrepancy, Bolton, tooth form, oral health, profile) (0.5point/item. More than 6 items = 3 points)	 3

 J	 Description of treatment duration and follow-up(1 point each)	 2

 K	 Description of limitations, biases andinaccuracies of the study	 1

 L	 Operator calibration	 1


Strain/Population	Wing length in mm (standard error)	Fecundity* (standard error)	Blood-meal size (μl) (standard error)

Mbita	2.86 (0.03)	35.97 (2.56)	3.15 (0.14)

Ifakara	2.89 (0.03)	49.27 (2.67)	2.54 (0.08)

F1 from Mbita female × Ifakara male	3.13 (0.03)	74.87 (2.63)	4.04 (0.16)

F1 from Ifakara female × Mbita male	3.03 (0.02)	83.20 (5.36)	4.51 (0.21)

F5 from Mbita female × Ifakara male	2.94 (0.02)	68.93 (2.61)	4.02 (0.16)

F5 from Ifakara female × Mbita male	3.14 (0.02)	68.77 2.69)	3.38 (0.18)


Sponge isolate	Inhibition zone diameter (mm)

S. aureus 8325	E. faecalis JH212	C. albicans S314

Actinokineospora sp. EG49*	0	0	12

Dietzia sp. EG67	13	0	0

Microbacterium sp. EG69*	10	9	0

Micromonospora sp. RV115	12	10	0

Rhodococcus sp. EG33*	12	8	0

Rubrobacter sp. RV113**	9	0	0

Streptomyces sp. RV15*	17	11	13


Meaning units	Condensed text	Themes

Has gained greater insight from the patients’ perspective to better understand and involve the patients Has developed and increased an awareness of nurturing the whole patient	An increased understanding of the patients’ perspective makes it easier to involve patients. The awareness of caring for the whole patient has increased	Focus on the patient perspective and paying more attention to others

Working in study groups motivates one to engage more in studies and provides greater learning	It is motivational and educational to work in study groups	Learning from discussions and reflections on one’s own learning


Citation	Type of study	Sample	Gene	Clinical assessments	Main findings

Tsao et al. 2006 [22]	Case-control and follow-up	20 MDD22 Controls	5-HTTIL-1βIL-6TNF-αIFN-α	Diagnosis based on DSM-IV criteriaHDRS	Higher expression of 5-HTT, IL-1β, IL-6, TNF-α and IFN-α in patients with MDD compared with controls. Significant decreased in expression of 5-HTT and IFN-α after 3 months of fluoxetine treatment.

Cattaneo et al. 2012 [23]	Case-control and follow-up	74 MDD34 Controls	IL-1αIL-1βIL-4IL-6IL-7IL-8IL-10MIFTNF-α	Diagnosis based on DSM-IV or ICD-10 criteriaSCAN	Higher expression of IL-1β, IL-6, MIF and TNF-α and lower expression of IL-4 in patients with MDD compared with controls.IL-β, TNF-α and MIF expression predicted antidepressant response.Significant decrease in IL-6 expression after 8 weeks of antidepressant treatment (escitalopram or nortriptyline) in responders only.

Suzuki et al. 2010 [25]	Case-control	43 MDD43 Controls	ApoER2VLDLR	Diagnosis based on DSM-IV criteriaHAM-DBPRS	Lower expression of ApoER2 in patients with MDD compared with controls.No significant difference in expression of VLDLR.

Galecki et al. 2012 [29]	Case-control	181 rDD149 Controls	COX-2MPONOS2APLA2G2A	Diagnosis based on DSM-IV criteriaor ICD-10 criteriaCIDI	Higher expression of COX-2, MPO,NOS2A and PLA2G2A in patients with rDD compared with controls.

Weigelt et al. 2011 [33]	Case-control	24 MDD22 BPD45 Controls	TREM-1DAP12PU.1ATF3EGR3MXD1MAFFNAB2	Diagnosis based on DSM-IV criteriaSCID-I	Higher expression of TREM-1 and NAB2 in patients with BPD only.Higher expression of PU.1 in patients with MDD and a trend for higher expression of TREM-1.Higher expression of ATF3, EGR3, MAFF and MXD1 in patients with both MDD and BPD.No significant difference in expression of DAP12 in either patient group.


Signaling questions	Answer	Risk of bias/applicability	Planned adjustment

Domain 1: Patient selection

Risk of bias	 	Low risk

Is a consecutive sample of patients enrolled?	Yes

Is a case-control design avoided?	Yes

Does the study avoid inappropriate exclusions?	Yes

Applicability	 	High concern	- Magnitude will be evaluated

Are there concerns that the included patients and setting do not match the topic of our study (patients had symptoms suggestive of inflammatory bowel disease in primary care)?

Domain 2: Index test

Risk of bias	 	Low Risk

Are the index test results interpreted without knowledge of the results of the reference standard?	Yes

If a threshold was used, is it pre-specified?	Yes

Applicability	 	Low Concern

Are there concerns that the index test, its conduct, or interpretation differ from the topic of our study (fecal calprotectin was measured with ELISA)?

Domain 3: Reference standard

Risk of bias	 	High risk

Is the reference standard likely to correctly classify the target condition?	No	 	- Probably not clinically relevant

- Adjustment in analysis[30,31]

Are the reference standard results interpreted without knowledge of the results of the index test?	Yes

Domain 4: Flow and timing

Risk of bias	 	High risk

Is there an appropriate interval between index test and reference standard?	No	 	- Represents care as usual

- Repeated measurement index test before endoscopy

Do all patients receive a reference standard?	Yes

Do all patients receive the same reference standard?	No	 	- Adjustment in analysis[30,31]


Strategy	Clusters of terms

 	#clusters	Interval	Mean

Semantic distance	7,564	[2; 1,354]	132.67

Terminology structuring	748	[1; 119]	3.82

(hierarchical+synonymy)

Merging (semantic distance +	7,684	[1; 1,354]	130.75

hierarchical + synonymy)


Land cover class	Description

Crops, agricultural and open savannah	Agricultural land or grassland with occasional trees/bushes (not seasonally flooding)

Woodland and dense savannah	Grassland with dense trees/bushes (not seasonally flooding) and patches of woodland

Built up and bare ground	Towns or villages with high building density or bare murrum or mud

Open water	Areas of open water

Lake fringe swamps	Lake edges with a high density of papyrus, water hyacinth and water lilies

Seasonally flooded grassland	Savannah which floods during the wet season, with occasional trees/bushes


No. of suicide attempts by self-poisoning per case (i)	0	1	2	3	4	5	6	≥7

No. of cases (ni)	---	1,069	334	156	78	32	15	30


	Baseline	Endline

Messages	Nutrition-focused MNCH2 (n = 747)	Standard MNCH (n = 767)	Nutrition-focused MNCH2 (n = 622)	Standard MNCH (n = 685)

Proper diet every day during pregnancy ensures weight gain of pregnant woman	77.5	78.5	97.1*	87.7

Proper diet every day during pregnancy ensures adequate growth of baby inside the womb	83.7	82.0	97.3*	90.4

Proper diet every day can ensure quick recovery of mothers after delivery	75.5	72.1	95.3*	86.0

Proper diet every day during pregnancy can save costs on doctor and medicine for both mother and child	46.3	49.3	84.7**	58.1

Proper diet during pregnancy will ensure that the child will be brainy	49.7	53.7	86.0**	61.9

Pregnant women should consume ≥5 different food groups daily	20.6	24.0	83.6***	16.4

Nutritious food is not always expensive	46.9	46.9	75.2***	46.1

During pregnancy, take 1 IFA tablet every day	83.7	78.6	95.8***	84.1

During pregnancy, take 1 calcium tablet every day	84.5*	79.4	96.6***	84.7

During pregnancy, take ≥2 h of rest every afternoon	75.2	70.9	91.6***	72.1

Avoid tea/coffee	14.1	13.0	50.3***	14.9

During pregnancy, a woman should gain 10–12 kg	17.1	26.0	83.6***	21.8

A pregnant woman should be weighed each month	30.5	36.4	84.9***	32.7

Total awareness score (range: 1–10)3	5.42 ± 2.12	5.47 ± 2.45	8.63 ± 1.89***	5.82 ± 2.12


Case	Age (years)	Sex	Physical activity	Level affected

1	9	Girl	Jumping rope	T5

2	9	Boy	Jumping rope	T6

3	10	Boy	Handstand	T11

4	11	Boy	Jumping rope	T7

5	12	Boy	Physical education	T4

6	13	Boy	Japanese box vaulting	T6


Characteristics	Mean	Standard deviation

Age (years)	25	1,0

Body mass index (kg/m2)	23,9	1,9

Waist size (cm)

 Male	79	5,0

 Female	76	2,0

Systolic blood pressure (mmHg)	114	10,0

Diastolic blood pressure (mmHg)	69	10,0

Estimated GFR (ml/min)	97,3	5,8

Alanine amino-transférase (UI)	28,1	1,7


Clone name	Comment

Rp11-91k4	Segmental duplication identified by BLASTN

Rp11-208g16	Segmental duplication identified by BLASTN

Rp11-119l2	Segmental duplication identified by BLASTN

RP11-168f7	Localization on other chromosome (chr19)

CDT-2278f18	Segmental duplication identified by BLASTN

RP11-129g16	Misplacement in database; real localization on 3q

RP11-79o5	Segmental duplication identified by BLASTN

RP11-666d14	Not functioning probe in any experiment

Rp11-153k19	Probe localized on other chromosome

Rp11-994b16	Segmental duplication identified by BLASTN

Rp11-732m7	Misplacement in database; real localization on 3p

Rp11-80p4	Localization on other chromosome (chr4)

Rp11-125e8	Segmental duplication identified by BLASTN


	Field hunting	Platform	Open room	Mantis	Net hole

Clutter	<10−10	<0.00005	0.58	0.07	<0.001

Net hole	<10−10	<0.00005	<0.001	0.33

Mantis	<10−10	<0.00005	0.2

Open room	<10−10	<0.00005

Platform	<10−10

Field hunting


Images	Training samples	Testing samples	Total

Liver cancer 	40	40	80

Normal cancer	60	60	120

Liver cirrhosis	60	60	120

Liver cyst	60	60	120


	Atrial Fibrillation (AF)*	Supraventricular tachycardia (SVT)**	Atrial Flutter***	Ventricular Ectopics

Female, n (%)	7 (28 %)	5 (20 %)	2 (8 %)	1 (4 %)

Male, n (%)	7 (28 %)	0	3 (12 %)	0


No.	Factor (g/L) 	Low level (-)	High level (+)

1	Isoeugenol	1	5

2	Dry Biomass	2.5	5

3	Tween 20	0	0.5

4	Tween 80	0	0.5

5	Glycerol	0	0.1

6	Yeast extract	0	0.1

7	Trypton	0	0.1

8	Cu+2	0	0.05

9	Zn+2	0	0.05

10	NaCl	0	50


Applications	Examples	References

Oil recovery	Microbial enhanced oil recovery (MEOR)Increase amount of recoverable oil aided by rhamnolipid-producing microorganisms	[73][2, 74]

Bioremediation	Bioremediation of petroleum at contaminated sitesAddition of rhamnolipids improves solubility of hydrocarbons to facilitate degradation	[46, 75–78]

Bioremediation of heavy metal at contaminated lands or in water treatment plant; rhamnolipids can be applied in foaming-surfactant technology to remove heavy metal contaminants	[2, 11, 79]

Bioremediation of pesticides at agricultural fields; addition of rhamnolipids can enhance degradation of chemical pesticides	[11, 79]

Pest control	As emulsifier, spreaders and dispersing agent in pesticide formulations	[2, 79]

As bio-pesticide against agricultural pests; rhamnolipids have insecticidal activity against green peach aphids and Aedes aegypti larvae	[43, 80]

Crop protection	As biocontrol agent against several phytopathogenic fungi; addition of rhamnolipids or rhamnolipid-containing cell-free broth are effective in inhibiting growth of phytopathogens, e.g. F. oxysporum, B. cinerea, Mucor spp. and many more	[1, 7, 81–84]

As stimulant for plant immunity; induced genes involved in plant’s defense system in tobacco, wheat and Arabidopsis thaliana; induced biosynthesis of plant hormones important for signaling pathways involved in plant immunity	[43]

Food processing	As food ingredients or additives functioning as emulsifier, solubilizer, foaming and wetting agent	[7]

As antimicrobial agent preventing food spoilage and for sanitization; rhamnolipids inhibit growth of foodborne pathogenic bacteria, e.g. L. monocytogenes, B. subtilis; rhamnolipids also prevent formation of biofilms due to their anti-adhesive nature	[1, 85, 86]

As a source of (l)-rhamnose; enzymatic hydrolysis of rhamnolipids to obtain (l)-rhamnose, a raw material for production of flavor compounds	[42, 87]

Medical use	As biofilm control agent to prevent medical device-related infections; inhibit biofilm formation; synergistic effect with caprylic acid to inhibit biofilms of more resistant pathogens, e.g. P. aeruginosa and S. aureus	[2, 88, 89]

As anticancer agent; rhamnolipids inhibit growth of many human cancer cell lines, e.g. HI-60, BV-173, SKW-3, JMSU-1 and Hela cells	[2, 19]

Protein folding	Aid in folding of outer membrane protein A	[90]

Microbial fuel cells	Improve power density output of microbial fuel cells	[91]

Synthesis of nanoparticles	As structure-directing agent in nanoparticle synthesis	[92]


Variables	N (%)

Sex	Female	16 (34.8%)

Male	30 (65.2%)

Age 30.5 ± 6.9 (mean ± SD)	23–28 year	26 (56.5%)

29–51 year	20 (43.5%)

Educational level	Diploma	20 (43.5%)

BPharm degree	25(54.3%)

MSc degree	1 (2.2%)

Work experience in community pharmacy (years) 5.6 ± 3.9 (mean ± SD)	1–4 year	22 (47.8%)

5–16 year	24 (52.2%)

Additional work experience	Yes	18 (39.1%)

No	28 (60.9%)

Employment status	Owner	18 (39.1%)

Employee	28 (60.9%)

Membership to any professional organization	Yes	15 (32.6%)

No	31 (67.4%)

Awareness of CPD concept	Yes	20 (43.5%)

No	26 (56.5%)


Sl. No:	Factors	Level description	Level	Contribution

1	Temperature (°C)	28	2	0.025

2	pH	5	2	0.081

3	Galactose (%)	0.8	1	0.223

4	Cupric sulphate (mM)	3	2	1.023

5	Inoculum concentration	6	2	0.117

6	Substrate length (m)	0.05	2	0.558

Total contribution from all factors	2.025

Current grand average of performance	54.743

Expected result at optimum condition	56.769


Variable (number of patients evaluated)		PD-L1 expression	p-value

Positive	Negative

Tumor stage (99)	High	2	14	0.66

	Low	8	75

	NA	0	4

Depth of stromal invasion (87)	> 1mm	4	32	0.16

	≤ 1mm	1	50

	NA	5	11

Lymph node involvement (71)	Present	4	27	0.69

	Absent	3	37

	NA	3	29

Metastasis (99)	Present	1	4	0.42

	Absent	9	85

	NA	0	4

Tumor grade (102)	High	9	81	1.00

	Low	1	11

	NA	0	1

Lymphovascular space invasion (88)	Present	0	8	0.59

	Absent	10	70

	NA	0	15

Haemangioinvasion (88)	Present	0	6	1.00

	Absent	10	72

	NA	0	15


Study 	Asthma therapy	Number of subjects	Results

Farah et al., 2011 [36]	Fluticasone/salmeterol	49	Similar improvements in asthma control, spirometry, airway inflammation, and airway hyperresponsiveness across BMI groups

Sutherland et al., 2010 [46]	Fluticasone, montelukast	1052	Fluticasone greater improvement across all BMI categories when compared to montelukast

Sutherland et al., 2008 [37] 	Glucocorticoids	45	Decreased in vitro response to glucocorticoids in obese asthmatics

Boulet and Franssen 2007 [35]	Fluticasone with or without salmeterol	1242	Fluticasone with salmeterol resulted in improved asthma control in both groups compared to fluticasone alone but overall decreased effectiveness with both regimens in obese patients

Dixon et al., 2006 [38]	Theophylline, montelukast, placebo	488	Increased risk of exacerbations in obese subjects treated with theophylline but no difference in montelukast treatment groups

Peters-Golden et al., 2006 [34] 	Beclomethasone, montelukast, placebo	 3073	Less improvement in asthma control days with inhaled corticosteroid with increasing BMI, no difference with montelukast


Quantity	Value	Description

z1	8 mm	Distance between the stem and the point light source [12]

z2	297 mm	Distance between the stem and the screen [12]

Δx	229 mm (for the stem width = 6 mm)	Width of the geometrical shadow [12]

Δp	5.2 μm	Camera pixel size

N	7 pixels	Response of a fringe position to the stem margin shift by 1 μm

C	38.125	Sensitivity of the optical set-up


ID	Farm	Age (months)	Sex	Weight (kg)	Previous episodes of BRD	Spontaneous cough	Nasal discharge	Abnormal lung sounds	Read number NS sample	Read number TTA sample

1a	TO1	14	M	400	3 months before sampling	Repeated	Cloudy and bilateral	Wheezes and crackles on the left side of the thorax	NP	53,494

2b	CN1	6	M	180	No	Absent	Absent	Absent	NP	7902

3a	CN1	6	M	180	1 month before sampling	Occasional	Absent	Wheezes and crackles on both sides of the thorax	NP	47,115

4b	CN1	6	M	180	No	Absent	Absent	Absent	NP	18,855

5b	CN1	6	M	180	No	Absent	Absent	Absent	NP	81,564

6a	CN2	6	M	180	No	Absent	Cloudy and unilateral	Absent	36,160	129,750

7b	CN2	6	M	180	No	Absent	Absent	Absent	28,543	118,454

8b	CN2	6	M	180	No	Absent	Absent	Absent	31,232	61,778

9a	CN2	6	M	180	No	Absent	Cloudy and bilateral	Wheezes and crackles on both sides of the thorax	DNA < 5 ng/μl	DNA < 5 ng/μl

10a	VC1	5	F	150	No	Repeated	Absent	Wheezes and crackles on both sides of the thorax	40,694	142,459

11a	VC1	5	F	150	2 months before sampling	Absent	Absent	Wheezes and crackles on both sides of the thorax	12,952	DNA < 5 ng/μl

12b	VC1	5	F	150	No	Absent	Absent	Absent	5988	DNA < 5 ng/μl

13a	VC1	5	M	150	No	Absent	Absent	Wheezes and crackles on both sides of the thorax	24,070	26,910

14b	TO2	6	M	200	No	Absent	Absent	Absent	DNA < 5 ng/μl	68,954

15b	TO2	6	F	200	No	Absent	Absent	Absent	20,464	40,790

16a	TO2	6	F	200	No	Absent	Absent	Wheezes and crackles on the right side of the thorax	167,198	107,679

17a	TO2	6	F	200	No	Absent	Cloudy and bilateral	Absent	DNA < 5 ng/μl	143,886

18b	TO2	6	M	200	No	Absent	Absent	Absent	3932	55,630

19b	TO2	6	M	200	No	Absent	Absent	Absent	DNA < 5 ng/μl	1,825c

20b	TO2	6	M	200	No	Absent	Absent	Absent	154,004	4585

21b	TO3	5	M	170	No	Absent	Absent	Absent	1,536c	6833

22b	TO3	5	M	170	No	Absent	Absent	Absent	159c	189c


CombinedPrograms	Single Program	t-value	Single Program	t-value

USR + GZD	USR	<underline>1.414</underline>	GZD	0.150

USR + PS	USR	<underline>1.373</underline>	PS	<underline>1.369</underline>

USR + ROCS	USR	2.489	ROCS	<underline>1.409</underline>

GZD + PS	GZD	<underline>1.409</underline>	PS	2.014

GZD + ROCS	GZD	2.402	ROCS	0.137

PS + ROCS	PS	3.547	ROCS	0.452


S.No.	Angiogenesis analyzer parameter	FRG1 overexpression vector	Control vector	P-value

1	Number of extremities	132 ± 25	107 ± 14	0.026

2	Number of nodes	263 ± 98	371 ± 96	0.039

3	Number of junctions	79 ± 28	110 ± 28	0.041

4	Number of master junctions	32 ± 16	46 ± 15	0.073

5	Number of master segments	51 ± 29	80 ± 28	0.057

6	Total master segment length	6288 ± 2837	9571 ± 2576	0.028

7	Number of meshes	16 ± 12	27 ± 12	0.057

8	Total mesh area	127029 ± 120136	306016 ± 163722	0.022

9	Number of pieces	183 ± 33	218 ± 36	0.052

10	Number of segments	83 ± 41	130 ± 43	0.039

11	Number of branches	69 ± 7	70 ± 8	0.41

12	Number of isolated segments	30 ± 11	17 ± 8	0.025

13	Total length	13624 ± 1677	15602 ± 1613	0.029

14	Total branching length	11200 ± 2393	14257 ± 2200	0.029

15	Total segment length	5964 ± 2756	9165 ± 2562	0.029

16	Total branch length	5236 ± 683	5091 ± 777	0.36

17	Total isolated branches length	2424 ± 867	1345 ± 620	0.014

18	Branching interval	87 ± 43	132 ± 41	0.046

19	Mesh index	200 ± 26	212 ± 28	0.22

20	Mean mesh size	6830 ± 1740	10358 ± 3523	0.024


cis-element	Position (From ATG)	Sequence (5′-3′)

Light regulation elements

 3-AF1 binding site	−1444(+)	ATGAGATATTT

 ACE	−1387(−)	CAAACGTATT

 AT1-motif	−511(+)	AATTATTATTTATT

 Box 4	−126(+),−560(+),−615(+),−752(+),−1183(+)	ATTAAT

 Box I	−390(+),−1363(+)	TTTCAAA

 G-Box	−156(+)	TACGTG

 I-box	−841(−)	GTAAAAGGCC

 LAMP-element	−63(+)	CTTTATCA

 chs-CMA1a	−1452(−)	TTACTTAA

Tissue-specific and development-related elements

 GCN4_motif	−1023(+)	TGAGTCA

 Skn-1_motif	−230(+),-1020(+),−1111(+)	GTCAT

 Circadian	−1220(+)	AAAAGATATC

 GARE-motif	−880(−)	AAACAGA

 TCA	−199(−)	GAGAATAATA

 ABRE	−156(+)	TACGTG

Abiotic stress response elements

 MBS	−1081(−),−649(+)	(C/T)AACTG

 HSE	−1307(−),−628(+)	A(A/G)AAAATTT(A/G)

 DRE	−170(+)	TACCGACAT

 TC-rich repeats	−1230(+)	ATTTTCTTAA


	Dentistry (N = 31)	Health Sciences (N = 22)	Pharmacy (N = 28)

Items	Mean	Agreement (%)	Mean	Agreement (%)	Mean	Agreement (%)

Q3_well_organized	3.14	100	3.38	100	3.23	92.4

Q4_safe_environment*	3.34	100	3.68	100	3.62	100

Q5_sufficient_information*	3.03	86.2	3.45	95.5	3.40	100

Q6_helpful_information**	3.11	96.4	3.68	100	3.58	100

Q7_engagement	3.89	88.9	3.9	90.5	4.00	100


Focus of Review	Methodological Rating

	Strong	Moderate	Weak	Total

Chronic Diseases (All)	329	144	141	614

Adult Health (All)	244	117	98	459

Child Health	208	86	75	369

Nutrition (All)	187	96	83	366

Addiction/Substance Use (All)	152	79	81	312

Physical Activity (All)	148	79	78	305

Adolescent Health	139	71	80	290

Mental Health (All)	156	75	53	284

Parenting, Infants and Children (All)	152	67	52	271

Injury Prevention/Safety (All)	166	57	43	266

Communicable Disease/Infection (All)	134	56	51	241

Reproductive Health (All)	131	43	40	214

Sexually Transmitted Infections (All)	81	48	58	187

Sexual Health (All)	87	46	38	171

Infant Health	81	32	23	136

Senior Health (All)	84	27	22	133

Healthy Communities (All)	43	26	29	98

Environmental Health (All)	39	10	14	63

Social Determinants of Health (All)	30	13	8	51

Dental Health (All)	28	9	10	47

Food Safety & Inspection (All)	8	2	2	12


Outcome measures	Operationalisation	Measurement

 	 	SCR	Qt	TIp

Usefulness

Population reached	General characteristics of the participants and trainers	+

 	Target population and proportion of the intended target population	+	+

 	Number of participants that refused, dropped out or completed training and reasons for withdrawal	 	+

Self-reported benefit or achievement	Benefit regarding the training according to trainers	 	+

 	Benefit regarding the training according to participants	 	 	+

 	Use of identification cane in daily life	 	+	+

 	Achievement regarding to training goals	 	+

Experienced barriers and potential solutions	Deviations of each session element*	 	+

 	Main goal, strong and weak aspects of the training	 	+	+

 	Hampering and encouraging factors of the standardised training*	 	+

 	Matters for improvement – materials and standardised training*	 	+

Acceptability

Extent to which intervention was performed according to protocol	Format, preparation time and duration of the session	 	+

 	Per session element: performance, duration and participation by participant*	 	+

 	Extent to which participant achieved training goals*	 	+

Participants’ exposure to and engagement in the training	Total number of sessions	 	+

 	Use of materials*	 	+

 	Opinion of trainer/participants regarding participant’s engagement	 	+	+

 	Extent to which participants complied with contracts*	 	+

 	Quality of action plans formulated by participant*	 	+

Opinion about the training	Overall opinion about the training by trainer and participant	 	+	+

 	Opinion regarding number, duration and progress of the sessions by trainer and participant	 	+	+

 	Opinion regarding comprehensibility of the training	 	 	+

 	Opinion regarding number of extra sessions needed and whether the participant’s need for mobility support was met	 	+	+

 	Burden experienced by participant	 	+

 	Recommendation of the training to others	 	+

 	Overall opinion about the trainer	 	+	+


	Heart Health Program	Traditional Hospital Cardiac Programs

Referral	No formal process, mostly word of mouth or opportunistic due to location.	Formal referral from doctor or cardiac nurse post cardiac event.

Attendance	As often as wanted, program runs weekly. No specific attendance required.	Set period, usually 4–6 weeks long. Attendance at every session usually required.

Health prerequisites	Nil, program provides information on any health issues requested by participants with primary focus on cardiac issues and diabetes. Do not need to have any chronic diseases or cardiac issues to attend.	Post cardiac event.

Transport	Provided to anyone who requires it at no cost.	Make own arrangements.

Food	Morning tea and lunch provided.	Not provided.

Exercise	Group walk and exercise-physiologist led rehabilitation exercises (walk pending weather).	Dependent on program.

Structure	Diabetes round-table discussion, followed by a group walk and morning tea. Group yarning on weekly health topic (session can be facilitator led, participant led, or a more formal presentation style talk depending on topic and presenter); lunch is provided during this session. Followed by weight exercises. Finished with a cardiac-specific discussion; sharing of personal experiences and asking questions is encouraged. Participants are free to leave at any point. Blood pressure and insulin measured throughout the day.	Typically PowerPoint presentation while seated at desks.


	Participated in FW (n = 2835)

(Reference category: Did not participate in FW)

OR (95% CI)

Demographics

Sex

Man	1.00

Woman	0.92 (0.76–1.13)

 Age	0.80 (0.78–.0.83)***

 Total years spent studying	0.70 (0.67–0.74)***

 Place of birth

Born outside of Norway	1.00

Born in Norway	0.79 (0.57–1.09)

 Religious identification

Nonreligious	1.00

Religious	1.01 (0.84–1.21)

 Relationship status

In a relationship	1.00

Single	1.29 (1.08–1.53)**

 Parental status

Did not have child/children	1.00

Had child/children	0.36 (0.23–0.56)***

 Educational institution

Not business school	1.00

Business school	1.60 (1.23–2.08)***

 Personality

ExtroversionZ	1.18 (1.07–1.29)**

AgreeablenessZ	1.08 (0.99–1.19)

ConscientiousnessZ	1.01 (0.92–1.10)

NeuroticismZ	1.01 (0.90–1.13)

Intellect/imaginationZ	0.96 (0.88–1.05)

Concurrent alcohol use (AUDIT-scoreZ)	1.28 (1.16–1.41)***

 Psychological health

Depression symptomsZ	1.08 (0.94–1.23)

Anxiety symptomsZ	0.93 (0.83–1.05)

Model, df = 16 and p < .001	Cox & Snell R2 = .390; Nagelkerke R2 = .536


Antibody	Identification	Dilution	Source

p16INK4a	E6H4	undiluted	mtm laboratories AG, Heidelberg, Germany

MMP-7	Clone ID2	1:30	Calbiochem, Merck Chemicals Ltd., Nottingham, UK

MMP-12	rabbit polyclonal	1:50	Sigma-Aldrich Inc., Saint Louis, MO

MMP-16	rabbit polyclonal	1:50	Sigma-Aldrich Inc., Saint Louis, MO

CK8/18	Clone 5D3	1:50	Novocastra Lab’s Ltd., Vision Biosystems, Newcastle, UK

Laminin	rabbit polyclonal	1:350	DakoCytomation, Glostrup, Denmark

EDA-Fibronectin	Clone 52DH1	1:30	Dr Ismo Virtanen [15]

E-cadherin	Clone 36	1:200	BD Transduction Laboratories, Franklin Lakes, NJ

N-cadherin	Clone GC-4	1:30	Sigma-Aldrich Inc., Saint Louis, MO

Beta-catenin	Clone 14	1:30	BD Transduction Laboratories, Franklin Lakes, NJ


Reference, Study Location and data collection period	Study Design Subject Characteristics and sample size	Exposure air pollutants	Health outcomes	Results	Adjustment for confounding factors	Limitations

Cross sectional studies

Karunasekara KAW et al.[40],Gampaha district.1998	Children, 5-11 years,asthmatics (n = 441);non asthmatics (n = 1510)	No specific types are measured	Asthma	Prevalence of asthma was significantly higher in the presence of firewood smoke	Yes	No measurement of exposure

Lankatilake KN et al.[20],Kotte Medical Officer of Health area.1999	Households = 397children = 604women = 130	Respirable dust	Respiratory symptoms	Respiratory symptoms were significantly higher in houses using firewood	Yes	Only respirable dust levels were measured

Pathirane S M et al.[43]Kegalle and Kalutara districts.2004	New borns (n = 369)	No specific types	Low birth weight	Low birth weight was associated with fuel type and kitchen characteristics	No	No measurement of exposure

Case-control Studies

Karunasekara KAW et al.[39],Colombo North Teaching Hospital1996-1997	Children 1-10 years,age matched cases and controls (n = 300)	No specific type	Asthma	Dust at home was a significant risk factor for asthma	Yes	No measurement of exposure

Perera MAKK P et al.[42],National Cancer Hospital2004	Lung cancer patients (n = 128) and controls (n = 128)	No specific type	Lung cancer	No significant association with biomass exposure	No	No measurement of exposure

Ranasinghe MH et al.[41], National Eye Hospital, Colombo2004	Patients with cataracts (n = 197) and controls (n = 190)	No specific type	Cataract	Cataracts significantly associated with biomass exposure	No	No measurement of exposure


Cropping system cultivar	Organic	Conventional	Average	Difference in organic

Mg ha−1	Mg ha−1	 Mg ha−1	%

Matt	2.13	2.85	2.48 b	−25.0

Saragolla	3.62	4.09	3.85 a	−11.4

Karalis	2.33	3.22	2.78 b	−27.6

Pablo	2.57	2.99	2.78 b	−14.2

San Carlo	2.46	3.45	2.94 b	−28.8

 Average	2.52 b	3.23 a	2.87	−21.0


Demographics

Age (yrs) (mean ± SD)		65.8 ± 8.7

Male/Female		46%/54%

Wealth (%)

	Poorest tertile	34%

	Tertile 2	20%

	Richest tertile	45%

BMI (kg/m2) (mean ± SD)		28.1 ± 4.9

Smoking status (%)	current smoker	11%

Chronic illness (%)		16%

Physical exercise

	Sedentary	2%

	Low	10%

	Moderate	52%

	vigorous	36%

Alcohol consumption

	Never	35%

	Occasionally	48%

	Daily	17%

Depression at baseline		11%

Depression at 4-year follow-up		10%

DHEA(S) (μmol/L) (mean ± SD)		2.41 ± 1.80


Medium	Carbon source	Rationale

DSMZ 65	Glucose Switchgrass MCC	DSMZ recommended T. bispora growth medium prepared with glucose

I/S	Glucose Switchgrass MCC	Previously reported actinobacteria isolation/screening medium prepared with MCC (Waldron and Eveleigh, 1986)

M9TE	MCC	Minimal medium + cellulose (Gladden et al., 2011)

DSMZ 84	Rolled oats	Previous DSMZ recommended T. bispora growth medium prepared with soluble polysaccharides from rolled oats


Inclusion criteria	Exclusion criteria

1. Written informed consent	1. Unstable asthma

2. Age 16 years or older	2. Presence of active lung disease other than asthma

3. Diagnosis of asthma by a health professional and duration of asthma symptoms ≥ 1 year.	3. Mental impairment or language difficulties that make informed consent impossible.

4. Asthma Control Questionnaire score (6 questions version) greater than or equal to 1 (suggesting poorly controlled asthma)	4. Terminal illness

5. Ability to access the internet (excluding via smart phone or tablet).	5. Cognitive impairment.


Species	Group	RG	RT	Skew1

Chromosomes with strongest overall skew

Candidatus Blochmannia floridanus	Gammaproteobacteria	0.433	0.107	0.446

Clostridium acetobutylicum ATCC 824	Firmicutes	0.426	-0.087	0.435

Ehrlichia canis str. Jake	Alphaproteobacteria.	0.346	0.226	0.413

Ehrlichia ruminantium str. Welgevonden	Alphaproteobacteria	0.360	0.191	0.408

Ehrlichia chaffeensis str. Arkansas	Alphaproteobacteria	0.360	0.191	0.407

Ehrlichia ruminantium str. Gardel	Alphaproteobacteria	0.353	0.190	0.401

Ehrlichia ruminantium str. Welgevonden	Alphaproteobacteria	0.349	0.188	0.397

Lactobacillus salivarius subsp. salivarius UCC118	Firmicutes	0.362	-0.121	0.382

Borrelia burgdorferi B31	Spirochaetes	0.229	0.300	0.378

Clostridium perfringens str. 13	Firmicutes	0.350	-0.086	0.360

Borrelia garinii PBi	Spirochaetes	0.207	0.287	0.354

Xylella fastidiosa Temecula1	Gammaproteobacteria	0.254	0.228	0.341

Bartonella quintana str. Toulouse	Alphaproteobacteria	0.300	0.080	0.311

Clostridium tetani E88	Firmicutes	0.273	-0.137	0.305

Bartonella henselae str. Houston-1	Alphaproteobacteria	0.284	0.080	0.295

Xylella fastidiosa 9a5c	Gammaproteobacteria	0.197	0.218	0.294

Lactobacillus acidophilus NCFM	Firmicutes	0.286	-0.024	0.287

Buchnera aphidicola str. Bp	Gammaproteobacteria	0.254	0.124	0.282

Lactobacillus johnsonii NCC 533	Firmicutes	0.260	-0.042	0.263

Carboxydothermus hydrogenoformans Z-2901	Firmicutes	0.260	0.000	0.260

Chromosomes with weakest overall skew

Corynebacterium efficiens YS-314	Actinobacteria	0.023	0.019	0.030

Nostoc sp. PCC 7120	Cyanobacteria	0.028	0.005	0.028

Sinorhizobium meliloti 1021 plasmid pSymA	Alphaproteobacteria	0.022	0.014	0.026

Mycobacterium avium subsp. paratuberculosis K-10	Actinobacteria	0.002	0.025	0.025

Anaeromyxobacter dehalogenans 2CP-C	Deltaproteobacteria	0.022	-0.009	0.024

Mycoplasma hyopneumoniae 232	Firmicutes	0.017	0.016	0.023

Mycoplasma synoviae 53	Firmicutes	-0.012	0.016	0.020

Wigglesworthia glossinidia	Gammaproteobacteria	0.016	0.011	0.020

Mycoplasma mycoides subsp. mycoides SC str. PG1	Firmicutes	0.017	0.009	0.019

Mycoplasma gallisepticum R	Firmicutes	-0.014	0.009	0.016

Aquifex aeolicus VF5	Aquificae	-0.006	-0.014	0.015

Mycoplasma hyopneumoniae 7448	Firmicutes	-0.012	-0.002	0.013

Thermosynechococcus elongatus BP-1	Cyanobacteria	-0.005	-0.010	0.012

Synechocystis sp. PCC 6803	Cyanobacteria	0.010	-0.002	0.010

Synechococcus sp. JA-2-3B'a(2–13)	Cyanobacteria	0.009	-0.001	0.009

Baumannia cicadellinicola str. Hc	Gammaproteobacteria	-0.003	-0.005	0.006

Anabaena variabilis ATCC 29413	Cyanobacteria	-0.005	0.003	0.006

Mycoplasma pneumoniae M129	Firmicutes	0.003	0.003	0.004

Synechococcus sp. JA-3-3Ab	Cyanobacteria	0.001	0.004	0.004

Gloeobacter violaceus PCC 7421	Cyanobacteria	0.003	-0.002	0.004


Adhesive systems

Name of the adhesive	Type of adhesives	Components

SBMP	ER, 3 steps	Phosphoric acid (35%)

Primer = HEMA, polyalkenoic acid copolymer, water

Bonding = HEMA, Bis-GMA, amines, photoinitiator

SB1	ER, 2 steps	Phosphoric acid (35%)

Adhesive (primer + bonding) = dimethacrylates, HEMA, polyalkenoic acid copolymer, silanized silicium, alcohol, water, photo-initiator

ADSE	SE, 2 steps	Primer = dimethacrylate, phosphonic acid acrylate, initiators, stabilizers

Bonding = HEMA, dimethacrylate, silicon dioxide, Initiators, stabilizers

ADSE-1	SE, 1 step	Derivates of bis-acrylamide, water, alcohol, bis-methacrylamide dihydrogen phosphate, amino acid acrylamide, hydroxyl alkyl methacrylamide, alkyl sulfonic acid acrylamide, highly dispersed silicon dioxide, initiators, stabilizers, and potassium fluoride


	2012 Logistic Regression Deviance	2012 Logistic Regression Deviance Rank	2013 Logistic Regression Deviance	2013 Logistic Regression Deviance Rank	2014 Logistic Regression Deviance	2014 Logistic Regression Deviance Rank	2012–2014 Logistic Regression Mean Deviance Rank

Age	17,739.3	1	16,378.7	1	15,230.7	1	1.0

Pneumococcal Vaccination	13,599.2	2	10,199.2	2	10,833.8	2	2.0

Time Since Last Checkup	8280.7	3	7738.6	3	7577.9	3	3.0

Number of Personal Doctors	1659.5	5	2014.3	4	1910.7	4	4.3

Employment	2244.6	4	1577.3	6	1749.8	5	5.0

Annual Household Income	1543.9	6	2013.3	5	1681.4	6	5.7

Smoking Status	680.7	8	785.3	7	772.3	8	7.7

Health Care Coverage	837.1	7	709.8	8	701	9	8.0

Highest Education Level Attained	616.5	9	707.6	9	773.2	7	8.3


	Non-op	Plate	TEN

Number	37	41	24

Age in years (stand. dev.)	41 (18)	38 (15)	34 (14.5)

Robinson classification 2B1/B2	24/13	14/27	17/7

Non-union (%)	2 (5.4)	0	1 (4.2)

Open reduction (%)		41 (100)	11 (46)

Other complications		1 lateral plate tear out after 4 weeks because of non-compliance	1 delayed union (healed with ultrasound), 2 lateral dislocations of the TEN, 1 prominent nail medially: required shortening in local anesthesia

Revision rate in % (major)		2.4	8.4 (4.2)


Variables	Number (%)

Male 	Female	Total

Presence of diabetes related complications 	48 (70.6)	141 (84.9)	189 (80.8)

Presence of two or more concurrent diabetes complications	18 (26.5)	115 (69.3)	133 (70.37)

Time of the diabetes related complication(s) diagnosis

 Before being diagnosed with diabetes	19 (27.9)	43 (25.9)	62 (32.8)

 After being diagnosed with diabetes	29 (42.6)	98 (59.0)	127 (67.2)

Type of diabetes related complication(s)

 Neuropathy	45 (66.2)	97 (58.4)	142 (75.0)

 Retinopathy	21 (30.9)	57 (34.3)	78 (41.4)

 Cardiovascular complications 	30 (44.1)	10 (6.0)	40 (21.1)

 Foot ulcers 	7 (10.3)	3 (1.8)	10 (5.1)


Medicine	Saving/unit (€)	Annual consumption	Annual saving (€)

IVIG	9.5/g	650 kg	6,175,000

Albumin	0.4/g	8,500 kg	1,360,000 (based on 40% market share)

FIX	0.04/IU	15 MIU	600,000

FVIII	0.02/IU	120 MIU	420,000 (based on 15% market share)


C+1354T single nucleotide polymorphism	Systemic sclerosis patients (n = 115)	Control individuals (n = 140)

Genotype*

 CC	103 (89.6)	108 (77.1)

 CT	12 (10.4)	30 (21.4)

 TT	0 (0)	2 (1.4)

Allele**

 C	218 (94.8)	246 (87.6)

 T	12 (5.2)	34 (12.4)


Metric		Observed	Predicted

Braiding intensity		6.8	6.4

Confluence node density, nodes km−2		91	83

Least squares regression coefficient of determination, R2, for relationship between:	Bar perimeter and bar area	0.986	0.985

Bar length and bar width	0.903	0.881

Bar convex perimeter	0.999	0.999


Treatment groups (mg/kg)	% MNPCE (mean ± SD)	% PCE (mean ± SD)

Nondiabetic control	0.32 ± 0.08	48.4 ± 1.81

Nondiabetic + naringin (25)	0.30 ± 0.07	48.2 ± 2.16

Nondiabetic + naringin (50)	0.28 ± 0.08	49.0 ± 1.41

Diabetes	0.92 ± 0.13**	45.6 ± 3.97

Diabetes + naringin (25)	0.60 ± 0.12a	47.0 ± 2.54

Diabetes + naringin (50)	0.44 ± 0.11b	47.4 ± 2.40


F0 male diet	CD	CD	HFD	HFD

F1 male diet	CD	HFD	CD	HFD

F1 Male offspring	n = 14	n = 14	n = 20	n = 19

 Total body weight (g)1	36.4 ± 0.8 a	39.8 ± 0.9 bc	37.7 ± 0.8 ab	42.1 ± 0.8 c

Reproductive organs

 Testes (g; L + R)	0.21 ± 0.01	0.20 ± 0.01	0.22 ± 0.01	0.22 ± 0.01

 Seminal Vesicles (g; L + R)	0.36 ± 0.03 a	0.38 ± 0.04 ab	0.41 ± 0.03 ab	0.46 ± 0.03 b2

 Gonadal fat depot (% TBW)	1.45 ± 0.21 a	2.68 ± 0.23 b	2.04 ± 0.21 a	3.91 ± 0.20 c

Sex Hormone

 Testosterone (ng ml−1)	2.51 ± 0.53	2.58 ± 0.41	2.41 ± 0.29	3.18 ± 0.28


Groups	Mean ± standard deviation (h)	p-value

Misoprostol	Foley catheter

Latent phase	8.5 ± 5.1	10 ± 6.8	> 0.1

Time to delivery	11.08 ± 5.6	13.6 ± 16.9	< 0.05


Microbial agent	Relative rate of incidence, n (%)

Early infections (39 episodes)	Late infections (187 episodes)

Coagulase-negative Staphylococci	20 (51.3)	56 (29.9)

Pseudomonas species	10 (25.6)	47 (25.2)

Sternotrophomonas maltophylia	6 (15.4)	30 (16.1)

Escherichia coli	/	15 (8.0)

Staphylococcus aureus	3 (7.7)	14 (7.5)

Enterococcus faecalis	/	9 (4.8)

Candida species	/	8 (4.3)

Enterococcus	/	4 (2.1)

Klebsiella pneumoniae	/	4 (2.1)


Drug [brand or alternative name(s)]	Common clinical formulation(s) (USA unless stated otherwise)	Classification; origin	Clinical use	Cellular target

Buprenorphine (e.g., Suboxone, Subutex, Buprenex)	Buprenorphine hydrochloride, buprenorphine naloxone (4:1)	Semisynthetic opiate; thebaine of the opium poppy (104)	Analgesia and maintenance therapy or opiate addiction treatment (Step 3 pain medication) (104)	Partial MOR agonist, KOR antagonist, nociceptin receptor agonist and antagonist (105, 106)

Fentanyl (e.g., Actiq, Duragesic, Fentora)	Fentanyl citrate	Synthetic opioid; N-phenethyl-piperidone (95)	Chronic and acute pain; administered orally, IV, transdermal patches (Step 3 pain medication) (107, 108)	Full MOR agonist, weak KOR agonist (109)

Heroin (i.e., diamorphine)	Diamorphine (UK) (110), diacetylmorphine (Canada/Switzerland) (111)	Opiate; morphine, and opium poppy (112)	Strong analgesic (Step 3 pain medication) (113, 114), opiate addiction treatment (Switzerland, Netherlands, Germany, England, Denmark) (115)	Partial MOR agonist (116) acts as prodrug (see active metabolites).

Hydrocodone (i.e., dihydrocodeinone) (e.g., Zohydro ER, Vicodin)	Hydrocodone bitartrate, hydrocodone bitartrate, and acetaminophen (117)	Semisynthetic opioid (118, 119); codeine (from opium poppy)	Chronic pain and opioid maintenance therapy (117)	Full MOR agonist (118)

Hydromorphone (e.g., Dilaudid)	Hydromorphone hydrochloride (120)	A semisynthetic opioid; the hydrogenated ketone of morphine (121)	Acute and chronic analgesia (Step 3 pain medication) (122), 5–8× more potent than morphine (123)	Full MOR agonist, partial DOR agonist, and weak KOR agonist (124, 125)

Methadone (e.g., Dolophine)	Methadone hydrochloride [(R) or racemic mixture] (126, 127)	Synthetic opioid (128); diphenylacetonitrile (129); and 1-dimethylamino-2-chloropropane (130)	Opioid dependence treatment (detoxification), chronic pain (131, 132)	Levo: full MOR agonist (109); dextro (d) NMDA antagonist (127).

Morphine (e.g., morphine sulfate ER, Roxanol, MsContin)	Morphine sulfate	Opiate; opium poppy (133)	Acute and chronic pain (Step 3 pain medication) (134)	Partial MOR agonist, weak DOR agonist (109, 135)

Oxycodone (e.g., Oxycontin, Norco, etc.)	Oxycodone hydrochloride, oxycodone acetaminophen, and oxycodone aspirin	Semisynthetic opiate; thebaine of the (136) opium poppy (137, 138)	Acute and chronic pain; may be superior than morphine for some types of pain (Step 3 pain medication) (139, 140)	Medium MOR agonist, partial KOR agonist (141), and partial DOR agonist (137, 142)

Remifentanil (e.g., Ultiva)	Remifentanil hydrochloride (always administered IV)	Synthetic opioid (143); derivative of fentanyl (144)	Acute pain or sedation (50–100× more potent than morphine) often used for surgical procedures (145–148)	Full MOR agonist (143)

Tramadol (e.g., Ultram)	Tramadol hydrochloride [racemic (+/−)], Tramadol hydrochloride, and acetaminophen	Synthetic opioid; salicylic acid with addition of 3-methoxyphenyl magnesium halide (149)	Moderate pain (Step 2 pain medication) (149, 150). Analgesic potency is 10% that of morphine (149)	(+/−) MOR agonist (151), (−) monoamine reuptake inhibitor (152)


Difficulties	Frequency (n = 59)**	Percentage

Institutional related

Few staff & heavy workload	20	33.9

Lack of testing kits and other logistical support	12	20.3

Occupational hazards (pricking self and infections)	7	11.9

Lack of prior sensitization before referral for testing	6	10.2

Poor motivation of staff	3	5.1

Lack of ARVs	2	3.4

Lack of child-friendly environment	2	3.4

Caretaker related

Unwillingness of caretakers to disclose to child	15	25.4

Caretakers refusing children to be tested	7	11.9

Caretakers look at HIV-infected children as a burden	3	5.1

Sick and weak parents	3	5.1

Clients not sympathetic to health workers due to desperation	2	3.4

Some parents deny parenthood (stigma)	2	3.4

Lack of consistency by caregivers	2	3.4

Child related

Children cannot express themselves easily	8	13.6

Dependency nature of children	6	10.2

Children require more time for counselling	5	8.9

Most children are needy & orphans	4	6.8

Need a lot of support to adhere to treatment	3	5.1

Children have many fears - death and abandonment	2	3.4

Health worker related

Failure to cope with knowledge demand for HIV care	14	23.7

Lack of specialized skills in paediatric counselling & management	10	16.9

Difficult of dealing with non-parents	7	11.9

Difficult to draw blood from children	4	6.8

Difficult to disclose to children	3	5.1

Caretakers refuse other monitoring tests for ART	2	3.4


Parameter	Value

Frequency	2.41 GHz

Transmitted Power Level	0 dBm

Antenna gain	5 dBi

Vertical plane angle resolution Δθ	1°

Horizontal plane angle resolution Δφ	1°

Reflections	5


Parameter, n (%)	Treatment-naïve patients

(N = 39)

At any time during study

 Increase from baseline ≥10 mm Hg	12 (30.8)

 Post-baseline IOP ≥25 mm Hg	15 (38.5)

 Post-baseline IOP ≥35 mm Hg	5 (12.8)

At final visit

 Increase from baseline ≥10 mm Hg	4 (10.3)

 IOP ≥25 mm Hg	4 (10.3)

 IOP ≥35 mm Hg	0 (0)

Glaucoma surgery (laser/incisional)	0 (0)

IOP-lowering medication used secondary to retina treatment	12 (30.8)


Consequence of muscle paralysis	Options for intervention

Motor weakness	Tendon transfer if muscle of adequate power (Grade V on the MRC scale) is available

Bracing if muscle of adequate power is not available

Muscle imbalance	Tendon transfer from stronger side of the joint to the weaker side of the joint if muscle of adequate power is available

Weaken muscles on stronger side of the joint if muscle of adequate power is not available for transfer

Instability of joint	Tendon transfer if:(a) Muscle of adequate muscle power available for transfer, (b) Instability is unidirectional (possibly bi-directional around ankle and foot)

Osteotomy to alter the biomechanics and restore stability (e.g., shifting the axis of movement of the joint)

Bracing if tendon transfer or osteotomy is not feasible

Arthrodesis (appropriate only for spine, shoulder, wrist and foot)

Deformity	Soft tissue contracture release (release of tendons, fascia, joint capsule)

Osteotomy for residual deformity after soft tissue release

Ignore if deformity contributes to stability (e.g., mild genu recurvatum or mild equinus in child with quadriceps paralysis)

Shortening of lower limb	Lengthening of short lower limb

Growth arrest of long lower limb

Compensate with shoe lift (especially if orthosis is required for shorter limb)

Ignore shortening in the upper limb and if <2 cm in the lower limb


 	Effect of Dex

 	Fold change of AQP5 mRNA	Fold change of AQP5 protein

Dividing cells

 <70% confluent	↓ 0–2x	↓ 0–2x

Nondividing cells

 90–100% confluent	↓ 4–6x	↓ 4–6x

 Matrigel treated cells	↓ 4–6x; after 2 h	↓ 4–6x; after 6 h


Characteristic	Value

Age, years	71 (51; 78)

Height, cm	169 ± 7

Weight, kg	74 (72; 85)

Body mass index, kg/cm2	26.4 (23.9; 30.1)

Sex

Male	21 (84%)

Female	4 (16%)

Simplified acute physiology score 2	29.2 ± 7.6

Type of surgery

Abdominal	10 (40%)

Vascular	5 (20%)

Endocrine	4 (16%)

Urologic	3 (12%)

Others	3 (12%)

Richmond agitation-sedation scale score

−1	9 (36%)

0	16 (64%)

Length of stay, days	2.6 ± 2.2

Length of mechanical ventilation, days	1.4 ± 0.9


	PDB Entry	5WZE

Data collection	Space group	P 21 21 21

	Cell dimension

	a, b, c (Å)	111.197,123.432,149.485

	α, β, γ (°)	90, 90, 90

	Wavelength	0.97776

	Resolution (Å)	48.01–1.783 (1.847–1.783)

	I/I	19.714 (2.167)

	Completeness (%)	0.99

	Rmerge	0.099 (0.709)

	Redundancy	8.9 (6.4)

Refinement	Resolution (Å)	48.01–1.783 (1.847–1.783)

	No. of reflections	194404 (18600)

	Rwork/Rfree	0.2105/0.2206

	No. of atoms

	Protein	1783

	Ligand/ion	90

	Water	1153

	B-factor

	Protein	27.37

	Ligand/ion	38.94

	Water	30.89

	R.m.s. deviations

	Bond lengths (Å)	0.011

	Bond angles (°)	1.00

	Ramachandran plot	98/1.5/0


		Test database MegaBLAST score

FAexpTRL	Annotation	Lp_MF	Zm_MF	Zm_TA	Hv_TA	Gm_TA	At_TA

LOC_Os04g16450	aquaporin PIP2.8, putative, expressed	470	357	351	838	121	121

LOC_Os04g16680	Sedoheptulose-1,7-bisphosphatase, chloroplast precursor, putative, expressed	289	995	1112	1112	184	129

LOC_Os04g16740	ATP synthase alpha chain, putative, expressed	1037	644	743	1126	856	815

LOC_Os04g16750	Photosystem I P700 chlorophyll a apoprotein A2, putative, expressed	613	868	644	628	470	462

LOC_Os04g16760	Photosystem I P700 chlorophyll a apoprotein A1, putative, expressed	503	1465	1100	323	357	252

LOC_Os04g16770	Photosystem Q, putative, expressed	936	190	539	1891	848	987

LOC_Os04g16780	Chloroplast 30S ribosomal protein S3, putative, expressed	129	287	474	498	97.6	141

LOC_Os04g16790	DNA-directed RNA polymerase alpha chain, putative, expressed	525	-	1086	1219	216	206

LOC_Os04g16819	DNA-directed RNA polymerase beta chain, putative, expressed	264	1265	410	394	105	188

LOC_Os04g16820	DNA-directed RNA polymerase beta chain, putative, expressed	1072	-	1096	460	266	-

LOC_Os10g21200	Photosystem Q, putative, expressed	936	1037	539	1883	840	979

LOC_Os10g21270	ATP synthase beta chain, putative, expressed	991	1524	1376	527	573	793

LOC_Os10g21280	Ribulose bisphosphate carboxylase large chain precursor, putative, expressed	936	591	1766	1701	531	981

LOC_Os10g21310	Photosystem II P680 chlorophyll A apoprotein, putative, expressed	561	287	551	170	206	-

LOC_Os10g21330	DNA-directed RNA polymerase alpha chain, putative, expressed	525	184	1070	1203	216	206

LOC_Os10g38229	Photosystem I P700 chlorophyll a apoprotein A1, putative, expressed	496	914	1092	323	357	252

LOC_Os10g38248	Photosystem I P700 chlorophyll a apoprotein A2, putative, expressed	1033	949	936	906	716	1076

LOC_Os10g38270	ATP synthase alpha chain, putative, expressed	1029	-	698	1098	848	815

LOC_Os10g38292	Chloroplast ATP synthase a chain precursor, putative, expressed	109	258	-	1096	545	614

Mean MegaBLAST score		214	260	504	473	155	151


Rank	Microbe	Evidence

1	Helicobacter pylori	PMID:24782613

2	Clostridium difficile	PMID:23734349

3	Prevotella	PMID:23613868

4	Actinobacteria	PMID:23613868

5	Staphylococcus aureus	PMID:16495627

6	Lachnospiraceae	unconfirmed

7	Staphylococcus	PMID:24385898

8	Haemophilus	unconfirmed

9	Bacteroides	PMID:20140211

10	Enterobacteriaceae	PMID:25759592


GO.ID	Term1	Corrected p-value2

GO:0050825	ice binding	< 1E-26

GO:0003677	DNA binding	4.01E-15

GO:0003700	transcription factor activity	1.26E-13

GO:0043565	sequence-specific DNA binding	5.79E-13

GO:0005199	structural constituent of cell wall	1.00E-08

GO:0004879	ligand-dependent nuclear receptor activity	3.15E-07

GO:0003682	chromatin binding	2.54E-06

GO:0003723	RNA binding	7.63E-05

GO:0008270	zinc ion binding	0.000303826

GO:0004969	histamine receptor activity	0.0008013

GO:0045735	nutrient reservoir activity	0.0008013

GO:0003702	RNA polymerase II transcription factor activity	0.001116964

GO:0003676	nucleic acid binding	0.001580342

GO:0003705	RNA polymerase II transcription factor activity, enhancer binding	0.009862154

GO:0003735	structural constituent of ribosome	0.02671

GO:0005249	voltage-gated potassium channel activity	0.049858667

GO:0004386	helicase activity	0.065105625

GO:0016563	transcription activator activity	0.13355

GO:0003714	transcription corepressor activity	0.13355

GO:0005179	hormone activity	0.199622105


	Factor 1 (Cardiopulmonary)	Factor 2 (Pain-fatigue)	Factor 3 (Gastrointestinal)	Factor 4 (Dysmenorrhea)

PHQ11: Shortness of breath	0.799

PHQ10: Palpitation	0.738

PHQ07: Chest pain	0.709

PHQ09: Fainting spells	0.661

PHQ03: Pain in extremities		0.689

PHQ02: Back pain		0.662

PHQ06: Headache		0.638

PHQ08: Dizziness		0.603

PHQ14: Sleep disturbance		0.594

PHQ15: Fatigue		0.524		0.520

PHQ13: Nausea or indigestion			0.715

PHQ01: Stomach pain			0.651

PHQ12: Constipation or diarrhea			0.612

PHQ05: Sexual problems			0.428

PHQ04: Menstrual cramps				0.822


Organ ischaemia and I/R injury	Expression of TLRs	Upregulation of TLRs in ischaemia	Evidence for role of TLR in pathophysiology	Potential endogenous ligand implicated in pathogenesis

Cerebral	Glial cells: TLR 1–9 [32, 33]Neurons: TLR 2 and 4 [34]	TLR 2, 4 and 9 [34, 35]	TLR 2 and 4 knockout mice have reduced infarct size following ischaemia [34, 36–38]	HSP 70 [34]

Liver	Hepatocytes: TLR 2, 3, 4 and 5 [39]Non-parenchymal cells: TLR 2, 3, 4, 5, 7 and 9 [39]	TLR 2 [40]	TLR 4 and 9 knockout mice are protected against ischaemia-induced liver injury [41–43]	HSP 72 [44] and HMGB-1 [42, 45]

Renal	Parenchyma: TLRs 1–10 at varying detection levels [46–48]	TLR 2 and 4 [47, 49]	TLR 2 and 4 knockout mice are protected against renal I/R injury, and this is associated with a reduction in inflammatory cytokine levels [49–52]	HMGB-1, hyaluronan and biglycan [49, 51, 53]

Myocardial	Myocytes: TLR 2, 3, 4 and 6 [54]	TLR 4 [55]	TLR 2- and 4-deficient mice show reduced myocardial infarct size [56–59]. TLR 4 antagonist eritoran leads to reduced infarct size, NF-κB nuclear translocation, and proinflammatory cytokine expression [60]	HMGB-1 [61]

Skeletal muscle	TLR 1–9 [62–64]	TLR 2, 4, 6 [65]	TLR 2 antagonsim reduces pro-inflammatory cytokine expression in an in vitro model of skeletal muscle ischaemia [65]	Under investigation


Clinical characterization	SOX2/TERC amplifications/polyploidy	Odds ratio (95% confidence interval), p (two-tailed Fisher exact test)

 	Normal	Polyploidy only	Amplification and poliploidy	Total abnormal FISH results	Normal vs. total abnormal FISH results	Normal vs. Polyploidy only	Normal vs. amplification with poliploidy

Controls	21	0	1	1	46.77 (5.91-370) 0.00	N/D2 (N/D2) 0.00	21.00 (2.56-455) 0.00

OSCC	22	27	22	49

Stage: I, II, III	8	7	8	15	1.29 (0.39 – 4.23), 0.78	1.25 (0.41-6.03) 0.76	1.00 (0.25-4.07) 1.00

Stage: IV	14	20	14	34

Stage: I, II	4	5	7	12	0.69 (0.17-2.77), 0.76	0.98 (0.18-5,13) 1.00	0.48 (0.09-2.34) 0.49

Stage: III, IV	18	22	15	37

Oropharynx	6	11	10	21	2.00 (0.59-6.93), 0.29	1.83 (0.47-7.46) 0.38	2.22 (0.53-9.52) 0.34

Outside oropharynx1	16	16	12	28


	Total population (N = 16)

Age [years]	N	16

Mean (SD)	62.5 (13.4)

Median (min, max)	67.0 (31, 76)

Gender [n (%)]∗	Male	7 (43.7%)

Female	9 (56.3%)

Duration of diabetes [years]	Mean (SD)	20.1 (7.6)

Median (min, max)	21.5 (2, 30)

Type of diabetes mellitus [n (%)]∗	Type 1	1 (6.3%)

Type 2	15 (93.7%)

Treatment of diabetes [n (%)]∗	Insulin	16 (100.0%)

Hba1c [%]	Mean (SD)	7.76 (0.7)

Median (min, max)	7.70 (6.3, 9)

Classification of diabetic retinopathy [n (%)]∗	Nonproliferative	14 (87.5%)

Proliferative	2 (12.5%)


 	%	Sun exposure	Localization	Clinical aspects	Colors	Histology

Superficial spreading melanoma	70	Intermittent	Back—Man Legs—Woman	Flat Papule Nodule	Tan, Brown, Gray, Black, Violaceous, Pink	Radial growth phase characterized by the proliferation within the epidermis of single atypical melanocytes in a pagetoid pattern

Nodular melanoma	5	Intermittent	Trunk Limb	Nodule Ulcerated polyp Elevated plaque	Brown Black Achromic	Radial growth phase absent

Lentigo maligna melanoma	4–15	Long term	Head Neck	Flat Papula	Brown Black	Radial growth phase composed of a lentiginous proliferation atypical melanocytes at the dermo-epidermal junction

Acral lentiginoso melanoma	5	N/A	Glabrous skin (palmoplantar, subungueal)	Flat Nodule Plaque	Irregular, poorly circumscribed pigmentation	Radial growth phase characterized by lentiginous proliferation of atypical melanocytes, marked acanthosis and elongation of the rete ridges of the epidermis

Desmoplastic melanoma	2	Long term	Head Neck	Papule Nodule	Erythemato us Flash colored Achromic	Vertical growth phase composed of atypical spindle cells embedded in a fibrous stroma

Melanoma arising from blu nevus	Rare	N/A	Head	Recent history of enlargement or change in pre-existing nevus	Blu-Black	Malignant dermal, deep seated component juxtaposed to a benign blue nevus

Melanoma arising in a giant	Rare	N/A	Trunk	Nodule growing in	Dark, brown	Dermal sharply delineated nodule

Congenital nevus	 	 	 	A nevus	Black	Composed of atypical ephitelioid, spindle or small cells, arising in a preexisting giant congenital nevus

Melanoma of childhood	0,4	N/A	Trunk	SSM or NM	SSM: Tan, Brown, Gray, Black, Violaceous, Pink	Conventional epithelioid melanoma or small cells or melanoma simulating Spitz nevus

Nevoid melanoma	1-2	N/A	Leg, trunk	Small papule	Tan to dark, brown	Nevus-like silhouette, limited intraepidermal component, loss/lack of maturation, cytological atypia, mitoses in the dermal component


	Variables	Measures used/source

Outcomes or responses	Musculoskeletal symptoms by body region	Modified from NIOSH symptom report items (NIOSH 2000)Hand diagram (Katz et al. 1990)

	Signs from physical exam	Modified from SHARP physical exam protocol (Viikari-Juntura 2000)

	MSDs	Combinations of signs and symptoms used to define working case definitions (Sluiter et al. 2001; Palmer et al. 2000 and Walker-Bone et al. 2002; Gerr et al. 2002)

	Acute work-related injury	Self-report

	Health-related quality of lifea	SF-12 (Ware et al. 1996)

	Upper extremity functiona	Upper extremity function scale (Pransky et al. 1997)

	Depressive symptomsa	CES-D (Radloff 1977)

Exposures	Work requirements Repetition, posture, force, temperature, tool use	Key informant interviews, project-specific self-report exposure tool

Modifiers	Work organization (decision latitude, control, demand, social support, job satisfaction)	Job Content Questionnaire (Karasek et al. 1998)

	Discrimination and response	Self-reported by race or gender and usual response (Krieger and Sidney 1996)

	Assertiveness at work	Scale measure from self-reported items; developed from key. informant interviews

	Coping style	John Henryism Active Coping Scale (James et al. 1987)

	Socioeconomic strain	Self-report of “Weeks you could be out of work without pay before loss of income would be a major problem.”

	Other health conditions	Medical history (select items based on possible relationship to MSDs—pregnancy, hormonal therapies, diabetes, etc.)


Type of intervention	Specific intervention	Votes	% of total votes

Other vaccines	None specified by any group	0	0

Information & skills	Lifestyle education	20	10

Oral health education (with or without provision of toothbrush and paste)	18	9

Diet & exercise education	17	8

Sexual & reproductive health and rights	12	6

Hygiene education (with or without provision of soap)	12	6

Health promotion through the school health programme	12	6

Road safety education	10	5

Education on mental health	8	4

Screening	Visual acuity	31	15

General health checks	15	7

Commodities & treatment	Deworming, including schistosomiasis and/or soil-transmitted helminth treatment	38	18

Youth-friendly services provision	12	6

Provision of school meals	3	1

Total		208	100


Protein	Sequence	NetCTLpansupertype prediction	Antigen specific T-cell response

HLA alleles assessed

NP	IPVYQVNNL	B7	B7: HLA-B*07:02

RLEELLPAV	A2	A2: HLA-A*02:01

FLSFASLFL	A2	A2: HLA-A*02:01

HPLARTAKV	B7	B7: HLA-B*07:02, HLA-B*35:01, HLA-B*51:01

GLFPQLSAI	A2	A2: HLA-A*02:01

FPQLSAIAL	B7	A2: HLA-A*02:01B7: HLA-B*07:02

QTNAMVTLR	A3	A3: HLA-A*03:01, HLA-A*11:01

KLTEAITAA	A2	A2: HLA-A*02:01

VP40	LPQYFTFDL	B7	B7: HLA-B*07:02, HLA-B*35:01

FTFDLTALK	A3	A3: HLA-A*03:01, HLA-A*11:01

“Pre-295 All GP”	ILFQRTFSI	A2	A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01

FLLQLNETI	A2	A2: HLA-A*02:01

“Post-295 GP”	MASENSSAM	B7	A2: HLA-A*02:01B7: HLA-B*07:02

LITNTIAGV	A2	A2: HLA-A*02:01

LANETTQAL	B7	B7: HLA-B*07:02, HLA-B*35:01

RTFSILNRK	A3	A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01

KAIDFLLQR	A3	A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01

VP24	VLSDLCNFL	A2	A2: HLA-A*02:01

L	IISDLSIFI	A2	A2: HLA-A*02:01, HLA-A*69:01

LLADGLAKA	A2	A2: HLA-A*02:01, HLA-A*69:01

HSGFIYFGK	A3	A3: HLA-A*11:01, HLA-A*31:01

KLINTLFHA	A2	A2: HLA-A*02:01

TPVMSRFAA	B7	B7: HLA-B*07:02, HLA-B*35:01

KPTFKHASV	B7	B7: HLA-B*07:02


Complete blood count	Coagulation

Erythrocytes	3.52 × 1012 cells/L	PT-INR	1

Hemoglobin	6.5 g/dL	aPTT	35 seconds

Hematocrit	27.7%	Fib	4.41 g/L

White blood cells	9.94 × 109/L	Other tests

Platelets	11 × 109/L	AST	35 U/L

Reticulocyte count	1.92%	ALT	19 U/L

		Cr	1.1 mg/dL

		Urea	40 mg/dL

		Na	140 mEq/L

		K	3.9 mEq/L

		Total bilirubin	1.0 mg/dL

		Uric acid	7.3 mg/dL

		Lactate dehydrogenase	183 U/L

		Ferritin blood test	148 ng/Ml

		Transferrin saturation	11.8%

		Serum iron	38 μg/dL

		B12 vitamin	668.4 pg/mL


Demographic characteristics	Cases	2008 population	Attack rate per 1000

Age	0–4	12	524	23

5–8	13	510	26

9–13	11	675	16

14+	29	3554	8

Sex	Male	42	2650	16

Female	23	2613	9

Total		65	5263	12


Demographic characteristics	N	%

Female gender	243	64.5

 	M	SD	Range

Age at study (years)	25.0	2.1	22.5 - 30.9

Disease characteristics	N	%	 	N	%

Congenital disorder	200	53.1	Daily medicine use	196	52.0

Perceptible disability	159	42.2	Medical aids/devices	184	48.8

Course of illness	 	 	Limitations in fingers/hand	148	39.3

Worse/variable	156	41.4	Limitation of sight	90	23.9

Stable/positive	221	58.6	Limitations of hearing	31	8.2

 	 	 	Able to sit half an hour	350	92.8

 	 	 	Able to stand half an hour	220	58.4

Chronic conditions	N

Visually impaired/blind	51

Spasm	45

Rheumatoid arthritis	45

Epilepsy	31

Back complaints	28

Hearing impaired/deaf	27

Intestinal complaints	21

CFS	20

Lung complaints	20

Accident damage	19

Paralysis	19

Cancer	18

Muscular dystrophy	17

Arthritis	16

Kidney diseases	13

Skin disease	9

Migraine	9

Heart disease	7

Other	119


HCH- isomers	Incubation period (days)	Degradation by isolate DAB-1Y (5 μg/mL) in %	Degradation by isolate. DAB-1W(5 μg/mL) in %

α	8	86	93

28	18	10

β	8	12	14

28	35	32

γ	8	94	98

28	30	28

δ	8	80	76

	28	32	28


	Odd ratio (95% CI)

Crude: Age < 50 years	1

< 50 years	8.14 (3.49~18.98)

 Gender - Male	1

- Female	2.36 (1.12~5.11)

 p-CagA - Sparse	1

- Weak	4.38 (1.15~16.72)

- Strong	8.34 (2.21~31.55)

Age and gender adjusted

 Sparse p-CagA	1

 Weak p-CagA	3.67 (0.93~14.37)

 Strong p-CagA	8.44 (2.08~34.12)

Age, gender and disease adjusted

 Sparse p-CagA	1

 Weak p-CagA	3.93 (0.92~16.94)

 Strong p-CagA	10.45 (2.25~48.48)


Surgery	Pre-surgery	Post-surgery	Median change

Control	0—11.0 ng/mL	NA	NA

Lumpectomy	0.1—15.8 ng/mL	1.0—53.8 ng/mL	4.8

Mastectomy	0.4—7.6 ng/mL	6.4—53.8 ng/mL	14.7


Possibilities causing anxiety	Frequency	Percentages	Mean state anxiety score

Fear of death	91	82.7	56.3 ± 8.2

Fear of unknown	58	52.7	57.8 ± 8.9

Financial loss due to hospitalization	47	42.7	54.7 ± 8.6

Results of operation	46	41.8	55.7 ± 7.9

Needing blood transfusion	43	39.1	57.4 ± 9.2

Concern about family	43	39.1	56.9 ± 6.9

Postoperative pain	43	39.1	55.7 ± 9.2

Change of environment	41	37.3	55.2 ± 7.7

Long waiting time for operation	40	36.4	54.9 ± 9.0

Unexpected events	39	35.5	55.2 ± 9.2

Being patient and coming to hospital	35	31.8	51.8 ± 8.9

Dependency	34	30.9	55.1 ± 8.7

Fear of physical disability	33	30	53.9 ± 8.7

Fear of complications	31	28.2	53.3. ± 7.3

Cancellations	31	28.2	54.6 ± 9.0

Alteration in body image	26	23.6	56.7 ± 7.5

Possible unknown diagnostic results	24	21.8	53.2 ± 6.6

Lack of information	18	16.4	51.3 ± 8.1

Nil per mouth	16	14.5	55.6 ± 1.0

Harm from doctor or nurse mistake	16	14.5	57.7 ± 8.8

Terminology and language used	16	14.5	53.8 ± 1.2

Sickness and vomiting	15	13.6	53.7 ± 8.3

Fear of not knowing what occurs while unconscious during anesthesia	14	12.7	52.8 ± 9.2

Concern about fellow patient	13	11.8	55.6 ± 9.2

Absence from work	13	11.8	55.7 ± 9.8

Inaccurate information	12	10.9	55.5 ± 8.9

Short waiting time for operation	10	9.1	56.1 ± 7.4

Getting stuck of needle	9	8.2	54.3 ± 1.2

Lack of knowledge of ward	9	8.2	51.3 ± 8.1

Not awakening from anesthesia	8	7.3	55 ± 1.2

Information from previous negative hospital experiences	8	7.3	55 ± 1.2

Familiarity with facilities	7	6.4	58 ± 7.1

Lack of recognition of staff	5	4.5	55.6 ± 6.7

Awareness during surgery	4	3.6	63.3 ± 2.5


Histone H3 Acetyl K9 1	Histone H3 Tri Methyl K4 2

Blocking solution 3: 5 min	Blocking solution 3: 5 min

primary antibody 1: 1:200 in PBS 5, incubation: 16 h, 4 °C	primary antibody 2: 1:500 in PBS 5, incubation: 16 h, 4 °C

PostBlock 3: 20 min	PostBlock 3: 20 min

HRP Polymer 3: 30 min	HRP Polymer 3: 30 min

Chromogen: DAB 4 (0.5 min)	Chromogen: DAB 4 (1 min)


 	 	Target concentration	Mean measured concentration

Net type	Chemical	Units	Mean	Range	Roof	Sides

PermaNet 3.0	Deltamethrin	g/kg	2.8 (sides)	2.1 - 3.5	-	3.1

g/kg	4 (roof)	3.0 - 5.0	3.9	-

Piperonyl butoxide	g/kg	25 (roof)	18.8 - 31.3	18.7	-

PermaNet 2.0	Deltamethrin	mg/m2	55	41.3 - 68.8	69.4	65.6

NetProtect	Deltamethrin	g/kg	1.8	1.4 - 2.3	1.6	1.6

Interceptor	Alpha-cypermethrin	mg/m2	200	150.0 - 250.0	171.0	251.0

Olyset	Permethrin	g/kg	20	17.0 - 23.0	21.0	21.6


Blood products within the first 24 h	Median [IQR]

 Red Blood Cells (Unit)	14 [11–19]

 Fresh Frozen Plasma (Unit)	12 [8–16]

 Platelet (Unit)	2 [1–3]

 Fibrinogen concentrate (gr)	4.5 [3–7.5]

Emergency procedures	N (%)

 Surgery for bleeding	206 (64)

 Embolization	83 (26)


Characteristic	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Case 8	Case 9

Sex	Male	Female	Female	Female	Female	Female	Female	Male	Female

Age (years)	41	44	36	45	43	51	49	31	37

Medical history

 Palpitations/headaches/sweating/hypertension	Yes	Yes	Yes					Yes

 Other			Type 1 neurofibromatosis		Takotsubo

Blood pressure at admission (mmHg)	160/120	180/108	157/107	130/110	140/100	130/85	141/107	160/100	129/99

Pre-ECMO LVEF (%)	5	20	15	20	30	20	20	30	20

Maximum troponin I (ng/L)	2200	34,000	43,000	15,000	2000	18,000	237	4994	2083

NT pro-BNP at admission (ng/L)			18,363		25,282	6363	18,471		9264

ECMO duration (days)	4	1	6	7	3	3	2	7	4

Urinary metanephrine (N < 340 μg/24 h)	ND	ND	ND	ND	1894	7192	8738	2862	2582

Urinary normetanephrine (N < 440 μg/24 h)	ND	ND	ND	ND	4973	3650	11,910	11,268	9254

Pheochromocytoma size (mm), side	78 × 75 × 70, right	60 mm, left	ND, autopsy	29, left	70, left	103 × 95 × 75, right	57 × 47, right	59 × 38, left	88 × 74×91, left


 	n	Days with absence from worka	Days with partial absence from workb	Total days affectedc	Percent absence from workd	Excess percent absence from work	FTE*

Mild/No Psychological Distress	2,463	0.6 (0.05)	1.6 (0.14)	1.4 (0.11)	5.0%	Reference	--

Moderate Psychological Distress	414	1.1 (0.10)	2.4 (0.32)	2.2 (0.25)	7.9%	2.9%	18

Severe Psychological Distress	226	2.1 (0.26)	3.1 (0.43)	3.6 (0.36)	12.8%	7.8%	23

Total Excess Absence from Work (FTE)	 	 	 	 	 	 	41


MIGS ID	Property	Term	Evidence codea

		Domain Bacteria	TAS [5]

		Phylum Cyanobacteria	TAS [6-8]

		Class Cyanobacteria	TAS [8,9]

	Current classification	Order Unknown

		Family 1.1	TAS [7]

		Genus Rubidibacter	TAS [1]

		Species Rubidibacter lacunae	TAS [1]

		Type strain KORDI 51-2	TAS [1]

	Gram stain	Not reported

	Cell shape	Rods	TAS [1]

	Motility	None	TAS [1]

	Sporulation	None	IDA

	Temperature range	25-35oC	TAS [1]

	Optimum temperature	30oC	TAS [1]

MIGS-6	Habitat	Seawater	TAS [1]

MIGS-6.3	Salinity	2-7% (optimum: 5)	TAS [1]

MIGS-22	OxygenCarbon sourceEnergy source	AerobicAutotrophPhototroph	TAS [1]TAS [1]TAS [1]

MIGS-15	Biotic relationship	Free living	TAS [1]

MIGS-14	Pathogenicity	None	NAS

MIGS-4	Geographic location	Chuuk state, Micronesia	TAS [1]

MIGS-5	Sample collection time	July, 2004	IDA

MIGS-4.1 	Latitude	7o 13’ N	IDA

MIGS-4.2	Longitude	151o 58’ E	IDA

MIGS-4.3	Depth	40 m	IDA

MIGS-4.4	Altitude	Not applicable	NAS


	Model 1:Demographics	Model 2:ACGs & Demographics	Model 3:ADGs, Sel. EDCs & Demographics	Model 4:2002 Expenditures & Demographics	Model 5:ADGs, Sel. EDCs, 2002 Expenditures & Demographics

2003 Top 0.5% Predicted User

Demographics	0.49%*	0.10%	0.03%	0.03%	0.02%

ACGs & Demographics		0.50%	0.07%	0.08%	0.06%

ADGs, 19 EDCs & Demographics			0.50%	0.19%	0.29%

2002 Expenditures & Demographics				0.50%	0.36%

ADGs, 19 EDCs, 2002 Expenditures & Demographics					0.50%

2003 Top 1% Predicted User

Demographics	1.00%	0.21%	0.11%	0.15%	0.11%

ACGs & Demographics		1.00%	0.30%	0.30%	0.32%

ADGs, 19 EDCs & Demographics			1.00%	0.40%	0.65%

2002 Expenditures & Demographics				1.00%	0.69%

ADGs, 19 EDCs, 2002 Expenditures & Demographics					1.00%

2003 Top 5% Predicted User

Demographics	4.96%*	2.43%	2.09%	2.46%	2.01%

ACGs & Demographics		5.00%	3.43%	3.02%	3.21%

ADGs, 19 EDCs & Demographics			5.00%	3.09%	4.06%

2002 Expenditures & Demographics				5.00%	3.73%

ADGs, 19 EDCs, 2002 Expenditures & Demographics					5.00%


	Patient’s results	Reference range

Immunoglobulin levels

 IgM, serum (mg/dL)	30	41–164

 IgA, serum (mg/dL)	68	14–122

 IgE, total (IU/mL)	10	< 60

 IgG, serum (mg/dL)	868	331–1164

Lymphocyte subset panel

 CD4+ lymphocyte (%)	43.3	23–48

 CD4+ lymphocyte count (/μL)	1115.74	500–2400

 CD8+ lymphocyte (%)	30.06	14–33

 CD8+ lymphocyte count (/μL)	788.49	300–1600

 CD 56+ cell (%)	12	4–23


Times until treatment	With complications	Without complications	Total

<24 hours	6	9	15

1-2 days	5	3	8

3–7 days	3	5	8

8–14 days	2	0	2

>15 days	5	2	7

Total 	21	19	40


Technical Characteristic	Value

Measurement range	30 m (indoors)/15 m (outdoors)

Measurement speed	43,200 points/second

Accuracy in the 3D representation	±0.1%

Field of view	270° (H) × 360° (V-in rotation)

Weight of head scanner	1.0 kg


mAb	Specificity/Reference	WT	vti13	prp3	prp3/vti13	csld2	csld3-2	xxt1	xxt2	xxt5

PECTINS

JIM7	High DE HG[31]	-	-	-	-	-	NA	-	-	-

LM19	Low DE HG[23]	++	++	+	++	-	NA	+	+	+

LM5	(1–4)-galactan[32]	-	-	-	-	-	NA	-	-	-

LM6	(1–5)-arabinan[33]	-	-	-	-	-	NA	-	-	-

INRA-RU1	Rhamnogalacturonan-I[34]	-	-	-	-	-	NA	-	-	-

XYLOGLUCAN

LM15	xylosylated XyG[29]	++	-	++	++	+	NA	-	-	-

LM25	galactosylated XyG epitope[20]	++	-	+	++	+	NA	-	-	-

MANNAN

BS-400-4	ß(1–4)-mannan/galacto-ß(1–4)-mannan[35]	-	-	-	-	-	NA	-	-	-

XYLAN

LM10	(1–4)-xylan[36]	++	-	++	++	++	NA	-	++	++

LM11	ß(1–4)-xylan/arabinoxylan[36]	+	-	+	+	-	NA	-	-	-

AGP

LM2	AGP[37]	-	-	-	-	-	NA	-	-	-

JIM13	AGP[38]	+	+	+	+	+	NA	+	+	+

JIM8	AGP[39]	+	+	+	+	+	NA	+	+	-

EXTENSIN

LM1	Extensin[40]	++	++	+	++	+	NA	+	+	+

JIM20	Extensin[41]	+	+	+	+	+	NA	+	+	+


	NS-TOPSAR	Sentinel-1	Airborne

	IW Mode	EW Mode	TOPSAR in [24]

Carrier frequency (GHz)	9	5.405	5.405	9.65

Altitude (km)	25	693	693	5

Resolution	4.5 × 4.5	5 × 20	20 × 40	2 × 1

(range × azimuth, m)

Swathwidth (km)	100	250	400	20

Revisit time	several hours	6 days	6 days	within one hour

Endurance	up to a few years	tens of years	tens of years	up to a few days


Variable	No. of patients (%)

Age, years (mean ± SD)	64.7 ± 13.7

Gender, male	24 (77.4)

Current/ex-smoker	15 (48.4)

Underlying disease	30 (96.8)

 DM	18 (58.1)

 Chronic lung disease	12 (38.7)

COPD/asthma	8 (25.8)

Old TB	2 (6.5)

Bronchiectasis	2 (6.5)

 Solid organ cancer	4 (12.9)

 Hematologic disease	4 (12.9)

 Liver cirrhosis	3 (9.7)

Systemic steroids before diagnosis	17 (54.8)

 Duration of steroids before ICU admission, day, median (IQR)	49 (14–90)

 Daily dosage of steroids, mg, median (IQR)	50 (29–71)

Inhaled corticosteroids before diagnosis	3 (9.7)

H1N1 infection before diagnosis	3 (9.7)


Codon position (HXB2 gp41)	Selection analysis method	Detected elsewherea

	SLAC	FEL	IFEL

24		B, D	B, D	T, C

54		B, F, CRF 02_AG	CRF 01_AE

96	C, D	C, A, D	C, B, D, CRF 01_AE	T

101	B, G	B, G	B, G

130	B	C, A, B	C, B	T

137	A, B	A, B, G	B	T

163	C, D, CRF 02_AG	C	C, D, CRF 02_AG	C

165	D, G		C, A, G

172		C, B, G, CRF 02 _AG

210	C, A, CRF 01_AE	C, A, B, D, F, G	C, D, CRF 01_AE

214b	A	A, B	A, B

221	G, CRF 01_AE	C, A, G, CRF 01_AE, CRF 02_AG	C, D, G, CRF 01_AE

230		A, D	A, G, CRF 01_AE

271		C, CRF 01_AE	C, B, D

328	C, B, G	C, B, G	C, B, G

332	A, B, G	A, B, G	B, D, G, CRF 01_AE	C

349		C, F, CRF 01_AE, CRF 02_AG	CRF 02_AG	C


Strain	Selected on:	Resistant to:

KWAG-base	No selection	-

KWAG-perm	Permethrin (0.75%)	Permethrin

MBN-base	No selection	DDT (low-level)

MBN-DDT	DDT (4%)	DDT, deltamethrin and permethrin (cross-resistance)


 	Adult patients	Elderly patients	P-value

Healthy donors, number	14	16

Age, y, mean ± SD	24.0 ± 8.1	78.4 ± 8.2	<0.001

Male, n (%)	11 (79)	11 (69)	0.45

Comorbidity, n (%)	0 (0)	5 (31)	0.30

Severe sepsis, number of patients	15	40

Age, y, mean ± SD	34.8 ± 11.9	77.6 ± 7.1	<0.001

Male, n (%)	12 (80)	28 (70)	0.45

Septic shock, n (%)	5 (33)	18 (45)	0.43

Ventilator rate, n (%)	11 (73)	31 (78)	0.75

APACHE II score, mean ± SD	19.2 ± 6.9	22.5 ± 6.9	0.14

 APACHE II-age score, mean ± SD	19.0 ± 5.0	15.8 ± 7.6	0.08

SAPS II score, mean ± SD	46.6 ± 17.5	58.6 ± 16.1	0.10

 SAPS II-age score, mean ± SD	43.3 ± 9.6	42.7 ± 11.6	0.17

SOFA score, mean ± SD	7.4 ± 4.6	7.3 ± 4.1	0.87

Comorbidity, n (%)	4 (27)	31 (78)	0.01

Types of bacteria detected in first 72 h, n (%)

 Gram-positive bacteria	8 (53)	22 (55)	0.91

 Gram-negative bacteria	15 (100)	40 (100)	1.00

 Fungi	6 (40)	17 (43)	0.87

Treatment, n (%)

Adjunctive hydrocortisone, n (%)	1 (7)	2 (5)	0.81

Organ support types

Ventilator, n (%)	12 (80)	35 (86)	0.48

Hemofiltration, n (%)	3 (20)	10 (25)	0.70

Organ support duration

Ventilator, d, mean ± SD	11.6 ± 12.3	9.3 ± 16.1	0.68

Hemofiltration, d, mean ± SD	7.3 ± 6.6	9.9 ± 12.8	0.26

ICU stay, d, mean ± SD	21.9 ± 22.6	16.6 ± 16.1	0.57

ICU-free days in 28 days, d, mean ± SD	11.6 ± 9.6	10.9 ± 11.6	0.64

Hospital stay, d, mean ± SD	36.3 ± 35.9	39.6 ± 41.9	0.41


In vitroresponse to:		ControlsN (%)	TST+, suspected LTBIN (%)	Cured TBN (%)

		13 (100)	106 (100)	29 (100)

QFT-IT

	Positive N.(%)	0	70 (66.03)	19 (63.3)

	IFN-γ (IU/ml) median (IQR)Among all	0 (0-0.1)	2.3 (0-15.1)	1.1 (0.1-4.2)

	IFN-γ (IU/ml) median (IQR)Among the positive responders	NA	8.1 (2.4-22.6)	3.8 (1.5-5.0)

RD1 proteins

	Positive N.(%)	0	64 (60.3)	19 (65.5)

	IFN-γ (IU/ml) median (IQR)Among all	0 (0-0.2)	1.4 (0.2-8.9)	1.6 (0.4-2.9)

	IFN-γ (IU/ml) median (IQR)Among the positive responders	NA	7.6 (2.3-20.3)	2.6 (1.6-6.2)


Unit*	Color¶	Day†	Positive culture‡	Leakage§

1	Red	None	No	No

2	Yellow/orange	30	Yes	Yes§

3	Yellow	9	Yes	Yes§

4	Red	None	No	No

5	Yellow/orange	19	Yes	Yes§

6	Orange	15	Yes	Yes§

7	Red	None	No	No

8	Orange	25	No	No

9	Red	None	No	No

10	Yellow	4	Yes	Yes§

11	Red	None	No	No

12	Red	None	No	No

13	Yellow	4	Yes	Yes§

14	Red	None	No	No

15	Yellow	13	No	Yes§

16	Orange	26	No	No

17	Orange	15	No	No

18	Red	None	No	No

19	Orange	30	No	No

20	Yellow	18	No	Yes§


Study population characteristics	mean (SD)

Gestational age (weeks)	32.5 (2.1)

Weight (g)	1700 (401)

Length (cm)	41.1 (3.3)

Head circumference (cm)	29.9 (1.6)

Apgar score at 1 minute	8 (1)

Apgar score at 5 minutes	9 (1)


Structure identifier	Description	No. of models	Reference(s)

U_1D3Z	Solution NMR ensemble	10	[35]

U_COCO	Solution NMR ensemble (1D3Z.pdb) plus COCO-derived conformers	20	this study

U_1XQQ	DER ensemble	128	[14]

U_2NR2	MUMO ensemble	144	[15]

U_2K39	EROS ensemble	116	[10]

U_ISD	ISD ensemble(ensemble provided as an example with the ISD 1.1 package)	25	[26]

U_NNR	NOE(2)+S2(8)+RDC(8) restrained ensemble	32	this study

U_CNS	RECOORD ensemble calculated with CNS	25	[34]

U_CNW	RECOORD ensemble calculated with CNS in water	25	[34]

U_CYA	RECOORD ensemble calculated with CYANA	25	[34]

U_CYW	RECOORD ensemble calculated with CYANA in water	25	[34]

U_1UBQMD	5ns MD simulation started from the X-ray structure 1UBQ	32	this study

U_1G6J	Ubiquitin in reverse micelles	32	[36]

U_1V80	Ubiquitin at 30 bar	10	[37]

U_1V81	Ubiquitin at 3000 bar	10	[37]

U_2JZZ	Solid-state NMR structure	20	[38]